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ABSTR~CT 
Bifidobacteria are administered in large quantities as probiotics, because they have many 
beneficial effects on human health. The growing interest in the health benefits of bifidobacteria 
has prompted the inclusion of these organisms in many dairy foods leading to an increase in their 
consumption. The survival of ingested microorganisms in the GIT influences the efficacy of 
probiotics. For bifidobacteria to survive and achieve colonisation, they have to interact with 
inhibitory host-produced substances such as bile salts. Another aspect which should be studied is 
the safety of the probiotic bacterium and risks of acquisition of genes for resistance to 
antimicrobial agents. Although bifidobacteria exhibit resistance to a wide range of antibiotics, 
little is known about the molecular basis for this resistance. The aim of this project was, 
therefore, to investigate the molecular mechanisms responsible for the resistance to antibiotics 
and bile salts observed in bifidobacteria, and more specifically, to determine whether efflux 
systems are involved in this resistance. 
Five Bifidobacterium spp. were exposed to a range of antimicrobial agents. These included 
ethidium bromide, the bile salt sodium glycocholate, and a range of antibiotics. Survival curves 
as well as intrinsic MIC values were determined in the presence of the antimicrobial agents. It 
was then determined whether pre-exposure to the antimicrobial agents resulted in an increased 
NIIC value for the antibiotic tested (adaptive MIC value). The resistance profiles displayed a 
great amount of interstrain and imerspecies variation in both the intrinsic and adaptive MIC 
values. Adaptation to at least one of the antimicrobial agents tested was observed in everyone of 
the bifidobacterial species. 
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To identify genes encoding antimicrobial efflux proteins, a genomic library of Bifidobacterium 
lactis hosted in the hypersusceptible strain Escherichia coli KAM3 was screened on tetracycline 
and ethidium bromide for colonies with increased resistance to either antimicrobial agent. Ten 
recombinant plasmids were isolated that conferred elevated levels of resistance to ethidium 
bromide. Sequence analysis was performed on all 10 plasmids. A putative ABC transporter 
system was isolated and further characterized. Attempts to measure the ethidium efflux of the 
transporter system proved unsuccessful in E. coli KAM3. The transporter was, therefore, 
subcloned into a Lactococcus laetis expression system. Expression of the ABC transporter 
system in a drug-sensitive L. lac tis strain did not complement the phenotype. 
Analysis of the Bifidobacterium longum NCC2705 genome sequence allowed the identification 
of putative efflux genes based on sequence similarity to known genes. Using this method, a 
putative sodiumlbile symporter was identified in B. longum. The gene, BLlI02, was isolated 
using a PCR amplification approach. BLit 02 was subcloned and expressed in E. eoli KAM3, an 
efflux negative mutant. The construct was shown to confer greatly elevated levels of resistance 
to sodium glycocholate (16-fold). Energy-dependent efflux of the bile salt was demonstrated 
using radiolabelled cholate. This is the first bile transporter described in bifidobacteria. The 
conditions under which BLil 02 is expressed could shed light on the role of this gene in the 
resistance of B. longum to bile in the human OIT. 
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1.1 GENERAL INTRODUCfION TO BIFIDOBACTERIA 
Bifidobacteria are natural inhabitants of the intestines ofwann-blooded animals and are also 
major components of the human intestinal microflora [Simon & Gorbach, 1984]. They are 
anaerobic, Gram-positive, rod like organisms with a characteristic Y - or V -shaped end 
[Scardov~ 19861. Bifidobacteria were first isolated from the stools of breast-fed infants. They 
are more prevalent in the intestines of infants and children than adults with a decrease in 
numbers of this microorganism with age [Hopkins et al., 2001]. 
1.1.1 Classification ofbifidobacterla 
Traditionally, bifidobacteria are considered to be lactic acid bacteria, since they produce 
acetic and lactic acid as the end products of glucose metabolism. This classification has not, 
however, been unanimously accepted. The genus Bijidobacterium is a member of the family 
Bijidobacteriaceae. The phylogenetic analysis of the genus is an ongoing area of 
investigation. Currently there are 35 species, including 6 subspecies assigned to the genus. 
When the 16S rRNA gene sequences of 31 of the type strains were analysed, almost all of the 
species formed a compact cluster with identity levels ranging from 93 to 99010. Only 2 
species, namely Bifidobacterium inopinatum and Bifidobacterium dentico/ens, did not share 
the high degree of sequence identity [Miyake et al., 1998]. Other gene sequences have been 
investigated for use as alternatives to 16S rRNA gene sequences in the phylogenetic analysis 
of the genus Bifidobacterium. One such gene is the highly conserved and ubiquitous HSP60 
gene IJian et al., 2001]. The partial HSP60 DNA sequence identity ofthe 36 Bijidobacterium 
strains studied ranged from 73 to 96%. Once again. B. inopinatum and B. denticolens did not 
fall into this range. These 2 species have been subsequently transferred to new genera, 
namely, Scardovia and Parascardovia respectively [Jian and Dong, 2002]. The taxonomic 
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standing of Bifidobactenum iactis and Bijidobactenum animalis is a subject of ongoing 
investigation Some studies have concluded that B. lactis and B. animal is are to be considered 
one single species. Other studies using methods such as protein profiling, atpD and groEL 
gene sequence analysis, BOX-peR fingerprinting, and Fluorescent Amplified Fragment 
Length Polymorphism (F AFLP), have demonstrated that representatives of B. animalis and 
B. lactis constitute two separate subgroups [Marco et al., 2004]. It has been suggested that 
B. anima lis be renamed Bijidobacterium animalis subsp. animalis subsp. nov. and B. lactis, 
Bifulobacterium animalis subsp. lactis subsp. nov. Such studies highlight that bacterial 
classification is in a state of flux. In this study the name B. lactis is used. 
1.2 GENETIC MODIFICATION OF BIFIDOBACTERIA 
The genetic manipulation of bifidobacteria is not \videly practised due to limited suitable 
replicating vectors and difficulties in transformation of the bacteria In addition, the DNA of 
bifidobacteria has a high mole percent O+C, ranging from 55-64%. 
1.2.1 Ve4::tors for Bifidobacteria 
Bijidobacterium longum and Bijidobacterium breve [Iwata and Morishita, 1989} are the only 
bifidobacteria of human origin that have been shown to harbour plasmids, for example pMB 1 
fromB. longum [Rossi et 01., 19%]. The replicon from pMBI has subsequently been used to 
construct improved cloning vectors, such as pDG7, as well as Escherichia coli-
Bijidobacterium shuttle vectors, such as pLF5 {Rossi et al., 1998]. A problem associated with 
pDG7 was that the success of transformation depended on the species of bifidobacteria used, 
the origin of the plasmid DNA, and the gene subcloned into the plasmid. For example, the 
cholesterol oxidase gene of Streptomyces spp. was cloned into pDG7, resulting in pDC07. 
Transformation of B. antmalis with plasmid isolated from E. coli was unsuccessful. 
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However, when pDC07 was purified from B. infantts, B. animalis was efficiently 
transformed [Rossi et at, 1998]. Other plasmids constructed from pDG7, purified from E. 
coli, did efficiently transform all Bifidobacterium spp. tested. The Escherichia coli-
Biji.dobacterium shuttle vectors constructed by Rossi et al. (1996) were able to express all the 
different antibiotic resistance genes used as markers. 
Other potential types of vectors that could be used in bifidobacteria would be those derived 
from closely related bacteria, or broad host-range plasmids. Argani et al. (1996) found that 2 
plasmids from the genus Corynebacterium replicated in bifidobacteria. They also tested 2 
broad-host range plasmids from Lactobacillus spp. and Lactococcus spp., but found that they 
did not replicate in bifidobacteria. This could be due to the AT -rich DNA of the 
microorganisms [Argani eta/., 1996]. 
Chemical mutagenesis with ethyl methanesulphonate (EMS) and N-methyl-N' -nitro-N-
nitroguanidine (MNNG) has been performed on bifidobacteria to increase p-galactosidase 
production [Ibrahim and O'Sullivan, 2000}. However, there has been no published data on 
gene deletions or site-directed mutagenesis of any bifidobacteria 
1.2.2 TransfonnatioD of bifidobacteria 
The uptake of exogenous DNA molecules can be prevented by the presence of a thick cell 
wall such as those possessed by bifidobacteria The cell wall ofbifidobacteria is composed of 
peptidoglycan layers, polysaccharides, lipoteichoic acids and proteins [Bezkorovainy, 1989]. 
The earliest successful protocol provided used electroporation, with competent cells needing 
to be frozen at -135°C for 1 hour lMissich et al., 1994]. A more reliable and efficient 
technique was later described, using an electroporation buffer containing ammonium citrate 
and sucrose. The cells were made competent by preincubation in eiectroporation buffer for 4 
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hours at 4°C [Argani et al., 1996J. A high sucrose concentration in the growth media as well 
as the electroporation buffer was shown to be essential. Subsequent procedures have been 
developed at the TNO Nutrition and Food Research, but have been patented (patent 
Application WO 95/35389) [Van der Werf and Venema, 2001] and are not widely available 
for research use. 
1.3 BENEFICIAL EFFECTS OF BIFIDOBACTERIA 
Bifidobacteria have been used successfully to prevent post-antibiotic complications, as well as 
intestinal diseases in bottle-fed infants who have been unable to establish normal intestinal 
flora [Saavedra et aI., 1994]. This is of particular importance in South Africa (SA) where 
bottle-feeding of infants is becoming more prevalent in response to fears of mother-to-child 
HIV transmission through breast-feeding. 
There are also claims that bifidobacteria have other beneficial effects on human health, in that 
they may play a role in preventing cancer [Wolloski et al., 1999], and in lowering blood 
cholesterol levels [Tahri et ai., 1995], which are prevalent as medical problems in SA. 
Bifidobacteria have been shown to inhibit the growth of pathogens, such as Escherichia coli 
0157:H7 [Kim et ai., 2001] as well enhance the immune system of the host [Ouwehand et aI., 
2002J, They are able to repress rotavirus infections [Saavedra et ai., 1994] and have positive 
effects on antibiotic-associated diarrhoea and restoration of gut flora after antibiotic therapy 
[Linskens et a!., 2001]. They have been to shown to alleviate lactose intolerance through the 
production ofJ3-galactosidases [Jiang et ai., 19%]. 
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1.4 PROBIOTICS, PREBIOTICS AND SYNBIOTICS 
1.4.1 Probiotia 
Bifidobacteria are generally considered to be good probiotic candidates. The use of live 
microbes as probiotics is a subject of intense and growing interest [Kullen et ai., 1997]. 
Although many different definitions of a probiotic have been proposed the most widely used, 
scientifically valid version is that of Fuller, 1991: "a live microbial food supplement that 
beneficially affects the host animal by improving its intestinal microbial balance". 
During the last 15 years the growing interest in the health benefits of bifidobacteria has 
prompted the inclusion of these organisms in many dairy foods leading to an increase in their 
consumption. 
An effective probiotic should 
• exert a beneficial effect on the host 
• be non-pathogenic and non-toxic 
• contain a large number of viable cells 
• remain viable during storage and use 
• have good sensory products 
• be isolated from the same species as its intended host 
• have colonisation potential in the human gastrointestinal tract (GIT) 
• be metabolically active within the OIT 
[Kailasapathy & Chin, 2000; Collins & Gibson, 1999} 
1.4.2 Prebiotics 
A prebiotic is a non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth andlor activity of one or a limited number of bacteria in 
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the colon. It modifies the composition of the colonic microflora in such a way that a few 
potentially health-promoting bacteria (especially, but not exclusively lactobacilli and 
bifidobacteria) become predominant, thereby benefiting the host [Kolisam et aI., 2002], 
Raffinose,lactulose, stachyose, :fructo-, isomalto- and galacto-oligosaccharides have all been 
reported to be effective in the proliferation of resident or implanted bifidobacteria 
[Crittenden & Playne, 1996]. 
Analysis of the Bijiobacterium longum genome, revealed that approximately 8.5% of the 
total predicted proteins are assigned to COGs in the carbohydrate transport metabolism 
[Schell et aI., 2002}. This suggests that the ability of B. /ongum to utilize non-digested 
carbohydrates in the human GIT is more extensive than previously anticipated. Genomic 
analysis data may, therefore, be used in the identification of possible prebiotics to stimulate 
the growth ofbifidobacteria in the human OIT. 
1.4.3 Synbiotics 
A synbiotic is a mixture of a probiotic and a prebiotic. This beneficially affects the host by 
improving the survival and establishment of live microbial dietary supplements in the GlT 
[Kailasapathy & Chin, 2000]. The combination improves the survival of the bacterial strain 
by providing a specific substrate for its fermentation For example, a fructooligosaccharide 
can be used in conjunction with a bifidobacterial strain. 
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1.5 SELECTION OF SUITABLE PROBIOTIC STRAINS: SURVIVAL AND SAFETY 
IN THE HUMAN GIT 
Survival in the human GIT, and safety concerns regarding the consumption of probiotic-
containing food products, are important factors in the selection of suitable candidate strains 
for use as probiotics. Other factors include the intrinsic properties of the strain, activity in the 
intestines, dose-response relationships, faecal and mucosal recovery, and the interactions 
between the strain and the host [Salminen et aI, 1998]. 
1.5.1 Survival in the human GIT 
The survival of a probiotic can be compromised in the supplemented product before ingestion, 
for example during storage, and even more so in the host after ingestion. The bacteria are 
confronted by many physiological conditions that may adversely influence its viability, 
including gastric acid and secretions of the small intestines such as bile salts and pancreatic 
enzymes [Collins & Gibson, 1999}. In addition, the bacteria must compete effectively with a 
complex and metabolically active indigenous flora present in the large intestine. The 
administration of antibiotic treatment directed at disease-causing bacteria can also 
compromise the survival of probiotic bacteria in the OlT. 
1.5.2 Safety concerns with tbe administration of probiotic bacteria 
Traditional dairy strains oflactic acid bacteria, including bifidobacteria, have a long history of 
safe use. However, new species and more specific strains of probiotic bacteria are constantly 
being identified, and it cannot be assumed that these strains share the same safety 
characteristics as other tested and traditional strains [Salminen et ai, 1998]. Even closely 
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related strains may have heterogenous qualities [Sullivan & Nord, 2002]. Therefore, safety 
aspects always have to be considered and constantly evaluated [Salminen et ai, 19981, and it 
is important to develop a science-driven, evidence based overview of the safety of 
bifidobacteria used as probiotics in food products [Borriello et ai, 2003]. One of the aspects 
which should be studied is the safety and risks of acquisition of resistance to antimicrobial 
agents [Sullivan & Nord, 2002]. 
1.5.3 Antimicrobial susceptibility of probiotic strains 
The antibiotic susceptibility of the probiotic is important for 3 main reasons; namely: the 
requirements for sustained survival during antibiotic treatment directed against disease-
causing organisms; the treatment of rare opportunistic infections; and also to evaluate the risk 
of drug resistance transfer to other colonic bacteria. 
The administration of antimicrobial substances can cause the suppression of certain beneficial 
bacterial groups, including bifidobacteria, which promote natural resistance of the host 
against infection [Lim et al., 1993]. Current evidence suggests that the risk of infection with 
pro biotic lactobacilli or bifidobacteria is similar to that of infection with commensal strains. 
However, it has been suggested that probiotic strains should be susceptible to at least 2 major 
antibiotics so as to treat the rare cases of probiotic-associated infections [Borriello et ai, 
2003). 
There are also safety concerns regarding the administration of bifidobacteria in high numbers 
in food products when such antibiotic resistance genes are present. It is currently difficult to 
interpret studies of gene transfer in viVO. and further methods need to be developed. Also, the 
focus should be on possible gene transfer to pathogenic bacteria such as Staphylococcus 
aureus, rather than on homologous gene transfer (Borriello et ai, 2003]. 
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L6ANnsIOTIC RESISTANCE 
colistmsulphate, fusidic acid, gentamyci:n, kanamycin, ~le, naladixic acid, 
neo~cin, norflaxin"paromomycin sulphate, polymyxin B, streptoll!Ycin, trimethoprim and 
vancomycin Resistance to tetracycline and 'l1itmfurantoinin the' strains studied ,~as variable 
[~harteris et ai, 1998; Lim et aJ, 1993} 
... . 
Although bifidobacteria exhibit resistance to a wide range of antibiotics, little is know about 
the molecular basis for this resistance. 
1.,6.1 Mechanisms of Antibiotic Resistance 
There are four major mechanisms by which bacteria in general can resist the effect of 
antibiotics, as illustrated in Figure 1.1 [Levy, 1998; Nell, 1992]; namely: inactivation of the 
antibiotic by destruction or modification of the antibiotic (A), alteration of the target site of 
, 
the antibiotic (B), prevention of drug influx (C), and active extrusion of the drug from the cell 
(D). 
FIGURE 1.1 Resistance mechanisms in bacteria comprise (A) drug inactivation, (B) target 
alteration, (C) prevention of drug influx, and (D) active extrusion of drug from cell [Putman 
et ai., 2000]. 
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Well-known examples of enzymes that inactivate antibiotics are P-Iactamases. These 
enzymes are located in the periplasm and confer resistance to J3-1actams such as penicillin and 
ampicillin [Reviewed. in Shah, 2004]. A single base change in a gene encoding a bacterial 13-
lactamase can change the substrate specificity of the enzyme [Davies, 1994]. These changes 
occur frequently, especially in Enterobacteriaceae species. This cycle of natural protein 
engineering changes in response to antibiotic-selection pressure. 
The most common mechanism of resistance is the development of altered forms of the normal 
targets that have increased resistance to antibiotics. Such resistance may involve the 
acquisition of new genes carried on plasmids or transposons that result in the enzymatic 
modification of the normal target Resistance to macrolide antibiotics, such as erythromycin, 
is caused by methylation of23S ribosomal RNA [Thakker-Varia, et ai., 1985]. 
The prevention of access of an antibiotic to the target by a barrier andlor the active transport 
functions of bacterial membranes confers a more general mechanism of drug resistance 
[Reviewed in Nikaido, 1994]. The bacterium can surround itself with a barrier of low 
permeability to decrease the influx of the drug into the cell. Gram-negative bacteria, such as 
Escherichia coli have the outer membrane, which functions as an effective barrier to 
antibiotics [Nikaido & Vaara, 1985]. 
In addition or alternatively to the prevention of drug influx, the antimicrobial agent can be 
pumped out of the cell before it can act. The resistance caused by energy-dependent 
transmembrane effiux of antimicrobial agents was first observed in E. coli with plasmid-
encoded tetracycline resistance [Speer et al., 1992]. These effiux systems will form the main 
focus of this review. 
15 
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1.7 MULTIDRUG EFFLUX SYSTEMS 
Unlike transporters such as the tetracycline efflux proteins [Speer (!t al:, 1992], which are 
dedicated systems mediating the extrusion of a given drug or class of drug, multidrug 
transporters can handle a wide variety of structurally dissimilar compounds. Bacterial 
multi drug effiux systems are a serious problem in the pharmacological treatment of patients 
with infectious diseases, since the substrate spectra of many multidrug transporters include 
clinically relevant antibiotics [Putman el aI., 2000l 
Active multi drug efflux systems in bacteria can. be divided into two major classes on the basis 
of bioenergetic and structural criteria [Putman et aI., 2000]. These classes are: 
• The secondary muhidrug transporters which extrude drugs using the proton motive force 
(PMF), and 
• The ATP-dependent multi drug transporters which are driven by the free energy of ATP 
hydrolysis. 1.fULTIDRUG EFFLl:JX SYSTEMS 
Seconcary multid11.lg 
transp orten 
I 
IvIFS SIvIR PJ,lD IvI.6. IE. 
r~ 
! 12 TI\~S 14 TIvIS 
. duster cluster 
I 
.6.1P-dependent multidrug 
transp orte:rs 
F •. B C superf.~nily 
FIGURE 1.2 Classification of muItidrug transporters into classes based on bioenergetic and 
structural criteria, and families based on supramolecular assembly mechanism and sequence 
homology. The secondary multidrug transporter class is divided into the Major Facilitator 
Superfamily (MFS), Small Multidrug Resistance Family (SMR), Resistance-Nodulation-Cell 
Division Superfamily (RND), Multidrug and Toxic Compound Extrusion Family (MATE). 
The MFS is further divided into the 12 and 14 transmembrane segment (fMS) clusters. All 
ABC transporters belong to-the ATP-binding cassette (ABC) superfamily [Nikaido, 1994; 
Putmail et af., 2000]. 
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As illustrated in .Figure 1.2, these classes are fm:therd:ivKled into families and clusters 00 the 
hasisof suptamolecular .assemblyand sequence similarity. Tbedru8cresistance profiles oflhe 
multidrug transporters vary strongly, and family-specific profiles-are not found. 
1.7.1 Sec.ondary multidrug transporters 
1.7.1,.1 Major Fadlitator Superfamily (MFS) 
The MFS consists of membrane transport proteins which are found in many organisms, from 
bacteria to higher eukaryotes. They are involved in the symport, antiport or uniport of various 
substances such as sugars, Krebs cycle intermediates, phosphate esters, oIigosaccharides and 
antibiotics [Marger & Saier, 1993]. The MFS proteins can be subdivided into two separate 
clusters, with either 12 or 14 transmembrane segments (TMS) as shown in Figure 1.2 and 
Table 1.1 [Paulsen & Skurray, 1993]. Figure 1. 3 shows a model of the structure of the 12 
TMS multidrug transporters of the MFS. 
FIGURE 1.3 Structural model for the 12-TMS multidrug transporters of the MFS. The 
residues constituting the conserved sequence motifs, A, B, C, D2, and G, are shaded [adapted 
from Putman et aI., 2000}. 
1.7.1.2 Small Multidrug Reslstante Family (SMR) 
Muhidrug transporters of the SMR family are most likely composed of a tightly packed four-
helix antipara11el bundle (Table 1.1) [Yerushalmi et al., 1996]. The protein sequences in the 
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SMR family are highly hydrophobic with very few charged residues most of which are found 
within putative loops [Paulsen et aI., 1996]. The family members bear few distinct signature 
sequence elements and several fully conserved residues. In some of the conserved residues, 
Ala-10, Glu-14, Tyr-60 and Trp-63, even replacements with a related amino acid bring about 
a loss of fimction.. Glu-14, which is the only conserved charged residue embedded in the 
membrane, is directly involved in the transporter coupling mechanism [Paulsen et at., 1996J. 
It has been proposed that the SMR family be placed in the druglmetabolite transporter 
superfamily. This superfamily consists of 14 families of which SMR is the best characterized 
drug transporter [Saier & Paulsen, 2001]. 
1.7.1.3 Resistance--Nodulation-Cell Division Family (RND) 
In Gram-negative bacteria, RND efflux pumps occur as part of a three-component system, 
where they are linked to an outer membrane channel protein by a membrane fusion protein, 
possibly via the two large periplasmic loops (fable 1.1). This protein complex allows the 
bacteria to extrude substrates directly into the external medium, bypassing the periplasm 
[Guan et al., 1999}. 
1.7.1.4 Multidrug and Toxic Compound Extmsion Family (MATE) 
In 1998, NorM was identified as a putative multidrug efflux protein in Vibrio cholerae 
[Morita et aZ., 2000]. This protein was shown to mediate norfloxacin efflUx. Although 
hydropathy analysis suggested the presence of 12 TMS, it did not exhibit any of the signature 
sequences. NorM was later identified as the prototype of a new family of transporters, the 
MATE family [Brown et aI., 1999]. However, this family's contribution to drug resistance 
has been shown only for a few isolated cases, for example BexA in Bacteriodes 
thetaiotaomicron [Miyamae et aI., 2001]. 
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TABLE 1.1 Classification of multidrug transporters according to sequence similarity and membrane topology 
--------
Class ATP-dependent Secondary 
£an1ilY ABC MFS SMR MATE RND 
-------
Cluster 12-TMS cluster 14-TMS cluster 
Reference [Hyde ef a/., 1990; Walker 1 Marger & Saier, 1993; [MargeI' & Saier, 1993; [Paulsen er al., 19%; [Morita ef al., 199XI 1 Fralick, 1996; Saier ef ai, 
to structure ef al., 19X21 Paulsen & Skurray, 19931 Paulsen & Skurray, )993[ SteinerMordoch et aI., 19941 
19991 
-~~ -------- -------
Structure Four domains: two Two homologous, each Two homologous, each Four transmembranc 12 transmembrane Two homologous, each 
highly hydrophobic containing six trans- containing seven trans- domains with short domains containing six trans-
membrane domains, membrane <:x:-hcliccs membrane a- helices loops in betwecn membrane a-helices 
consisting of six trans- with two large 
membrane helices cytoplasmic loops 
each, and two 
hydrophilic nucleotide- Occur as part of three-
binding domains component system 111 
(NBDs) Gram-ncgative bacteria 
Consensus NBDs contain Walker A A: 0 x LaD r x 0 r k x A: 0 x LaD r x 0 r k x A: W i x I v I II E V A: 0 x s x v T v x F x x g t J) x 
sequences and B motifs and 
x (xJ I x (x) I xxAqvqVqllkLqxxLP 
H: K x s c G F t r I x P S xxVqxqgxxvxk 
of ABC signature U: I x x x R x x q G x g a a H: I x x x R x x q G x g a a 
conserved c: P v 0 t A Y A v W t 0 H: a I v I S 11 V F I P III a f f g G 
motifs 
C:gxxxGPxxGGxxG C:gxxxGl'xxOGxxG 10 xtGxiyrqfslTxvsAllla 
G x I G x I ISvxvaltltPAIc.:A 
D2: I g x x x x x P v x P Dl:IDxTvXllVAIP c: x x x 0 k x I x c A x x x a a x 
xRLRPILMTsLafllGv 
(;: 0 x x x G P L E: J) x x G x xL IPlaiatOxAGa 
F: I g x x x 0 x 11 V X g x I D: SIN tiT I f g I v I a i G L I 
vDDAIVvVENvcRvla 
II: W x w x F I I N v Pig c 
Size 590 an residues 338 aa residues 513 aa residues 107 aa residues 403 aa rcsidues I 000 aa residues 
~~~~ -----
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1.7.2 ATP-dependent multidrug transporters 
Unlike most bacterial multidrug transporters that utilise the PMF or sodium ions for the 
extrusion of antimicrobial agents, some drug efflux systems are driven by the free energy of 
ATP hydrolysis. All ATP-dependent drug efflux proteins known to date are members of the 
A TP-binding cassette (ABC) superfamily [Higgins, 1992]. ABC transporters form one of the 
largest of all protein families with substrate specificities ranging from the uptake of sugars, 
amino acids and inorganic ions to the export of large protein toxins [Bolhuis et al., 1994]. 
The ABC superfamily currently includes 21 families of prokaryotic efflux systems 
[Saier & Paulsen, 2001]. Two well-characterized ABC nmltidrug transporters are found in 
the Gram-positive lactic acid bacteria Lactococcus lactis and Lactobacillus brevis (Table 1.2). 
TABLE 1.2: Reported drug resistance profiles of ATP-dependent multidrug transporters a 
[adapted from Putman et al., 2000]. 
ABC transporters 
Drugs HorA LmrA 
Lactobacillus brevis Lactococcus. lactis 
[Sakamoto et al., [poelerands et al., 
2001 ] 2000} 
Aminoglycosides + 
~ -Lactams 
Carbapenems -
CephalospQrins + 
Penicillins + 
Chloramphenicol - + 
Glycopeptides -
Hop compounds + 
Lincosamides + 
Macrolides 
14-membered - + 
IS-membered + 
Monovalent cations + + 
Novobiocin + 
Quinolones 
Hydrophilic + 
Hydrophobic + 
Tetracyclines - + 
Trimethoprim -
a reSIstance; -, no resIstance 
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The transporters have an N-terminal hydrophobic domain consisting of six putative 
transmembrane helices and a C-tenninal hydrophilic domain, containing the ATP-binding 
cassette (Table 1.1). This latter domain contains features diagnostic of an ATP-type ATPase, 
such as the ABC signature sequence and the Walker A and B motifs [Walker et ai., 1982]. 
1.7.3 Origin and regulation of mnltidrog transporter genes 
Multidrug transporters are associated with both intrinsic and acquired resistance to antibiotics. 
Acquired multidrug resistance can arise via three mechanisms: (i) amplification and mutation 
of genes encoding multidrug transporters, changing the expression level or activity [Putman et 
al., 2000], (ii) mutations in specific or global regulatory genes which lead to the increased 
expression of multidrug transporters [Poole et al., 1996], and (iii) intercellular transfer of 
resistance genes on transposons or plasmids [Kazama et al., 1998}. In addition, the 
expression of several genes encoding multidrug efflux pumps is inducible by the drugs to 
which they offer protection [Zheleznova et ai., 1999]. The expression of some multidrug 
transporters can also be modulated in response to environmental conditions [Baranova et al., 
1999]. 
Addition of the compounds exported by the multidrug transporters themselves actually 
enhances the expression levels of multidrug transporters. This has been shown for both Brnr 
from Bacillus subtilis [Ahmed et aL, 1994J and QacA from Staphylococcus aureus [Grkovic 
et aI., 1998J. These observations indicate that the expression of muItidrug transporters is 
controlled by regulatory proteins which, like the transporters, are capable of recognizing 
structurally diverse compounds. 
A comparable ability to bind diverse hydrophobic cationic drugs is characteristic of the B. 
subtilis transcription regulator, BrnrR, which upon binding activates expression of the 
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multidrug transporter, Bmr [Zheleznova et al., 1999]. BmrR, which is encoded by a gene 
immediately downstream of bmr, belongs to the MerR family of regulators and has strong 
homology with otlier members of the family only in the N-terminal helix~tum-he1ix PNA-
binding domain [Ahmed et aI., 1994]. The inducer-binding, C-terminal domain ofMerR-type 
proteins are dissimilar, which allows them to participate in a wide variety of respQJlSes, for 
example, to mercury ions (MerR), flavonoids (NolA) and oxidative stress (SoxR). The C-
terminal-of1lmrbmd-s-a-var-iety-ofstIuclmally diveIse hydrophobic cations, including many 
toxins transported by Brur, thus allowing the expression of the transporter to be enhanced by 
many of its toxic compounds [Ahmed et aI., 1994J. Crystal structures of the mQItidrug-
binding domain of BmrR, and of its complex with the drug tetraphenylphosphonium (TPP+), 
revealed a drug-induced unfolding and relocation of an alpha helix, which exposes an internal 
drug-binding pocket. TPP+ binding js mediated by stacking and van der Waals contacts with 
multiple hydrophobic residues of the pocket, and by an electrostatic interaction between the 
positively charged drug and a buried glutamate residue, which is the key to cation selectivity. 
Similar binding principles may be used by other multidrug-binding proteins [Zheleznova et 
al., 1999]. 
Rhodamine 60 is a substrate of Bmr. Binding of one rhodamine 60 molecule to a dimer of 
BmrR increases the affInity of BmrR for the bmr promoter, resulting in enhanced 
transcription of the bmr gene [Ahmed et al., 1994]. The individually expressed C-terminal 
region ofBmrR forms dimers and binds a broad range of drugs with the same affinity as full-
length BImR [Zheleznova et ai., 1999]. 
B. subtilis also expresses another multidrug transporter, BIt, which is specifically controlled 
by another MerR-type regulator, BltR Both BmrR [Zheleznova et ai., 1999] and BltR 
[Baranova et at, 1999J are encoded in the vicinity of their corresponding transporter genes,. 
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Specific regulatory mechanisms that affect the expression of single multidrug transporters are 
not the only way of controlling the level of gene expression. Induction of multidrug efflux 
systems can also result from global regulatory mechanisms. In addition to regulation by BltR 
and BmrR, both BIt and Bmr are controlled by a global MerR-type regulator, Mta [Baranova 
et al., 1999]. The N-terminal domain of Mta (MtaN), when expressed separately, acts as a 
constitutive activator of the transcription of bmr and bIt genes as well as of its own 
transcription and the transcription of at least one other gene, ydfK. The full-length Mta does 
not possess such an activity. It has been suggested that the separation of the N-terminal 
domain of Mta from its C-terminal domain mimics the activation of Mta occurring naturally 
upon binding of its hypothetical inducer, which has yet to be identified. Mta-mediated 
regulation could either provide protection from a specific environmental toxin or control 
normal bacterial physiological processes [Baranova et al., 1999]. The control of Bmr and BIt 
expression by at least two independent regulatory mechanisms is similar to the control of the 
E. coli multidrug transporter, AcrAB, by a specific regulator, AcrR, and by two global 
regulators, MarA and SoxS [Okusu et aI., 1996]. 
The multiplicity of control mechanisms suggests that the bacterial cell takes advantage of the 
broad substrate specificity of each multidrug transporter and uses it to transport different 
substrates, depending on the physiological needs of the cell [Baranova et al., 1999]. The 
multiplicity of similar multidrug transporters in the same cell may originate from the 
recruitment of duplicated copies of an earlier multidrug transporter gene into different 
operons, in which they are placed under different regulatory controls and become involved in 
different functions, as seen with Bmr and BIt. The existence of a global regulator, Mta, 
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indicates that at least some of the functions of these transporters remain either identical or 
closely related. 
1.8 RESISTANCE TO BILE 
The survival of ingested microorganisms in the OIT influences the efficacy ofprobiotics. For 
bifidobacteria to survive and achieve colonisation, they have to interact 'with inhibitory host-
produced substances such as bile salts [Margolies et aI., 2oo3J. Bile concentrations range 
from 0.5% to 2.0% in the first hour of digestion and the levels may decrease during the 
second hour [Kailasapathy & Chin, 2000]. Bile is a digestive secretion that plays a major role 
in the dispersion and absorption of fat-soluble vitamins, lipids and cholesterol. The 
composition of bile is complex, but can be thought of as lipid rich and protein poor. Lipid 
molecules found in bile include cholesterol, phospholipids and bile acids, while 
immunoglobulins are one ofthe major protein constituents [Hofmann, 1998]. 
Bile acids are synthesized from cholesterol in the liver and secreted into bile. This is stored in 
the gallbladder until ingestion of a fatty meal when they enter into the lumen of the 
duodenum Most of the bile salts are absorbed from the duodenum and returned to the liver 
via the portal circulation [Hofmann, 1984]. The remaining part of the bile salts is 
deconjugated by the action of bile salt hydrolases present in enteric bacteria, with the 
formation of the corresponding free bile acids such as cholate and chenodeoxycholate 
[Doerner et al., 1997]. The free bile acids are further metabolized by some members of the 
intestinal bacteria into secondary bile acids such as deoxycholate and lithocholate [Franklund 
et aI., 1993]. 
Bile acids are surface active, amphipathic molecules, and are, therefore, a type of detergent. 
As such, they possess potent antimicrobial activity as they disaggregate the ordered structure 
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of biological membranes. However, enteric flora and pathogens have developed mechanisms 
to resist the action of bile [Gunn, 2000~ Yokota et aI., 2000l 
Bile resistance is of importance to many fields of interest since the survival of ingested 
microorganisms in the gastrointestinal tract influences the risk of food-bourne infections and 
the efficacy of probiotics and orally dosed live vaccines [Marteau et aI., 1997J. The 
resistance of enteric bacteria to bile has been known for decades, however, relatively little is 
kno,,"ll about its molecular basis. The effect of bile on Gram-positive bacteria is not well 
lIDderstood, but some of the resistance mechanisms found in Gram-negative bacteria are 
likely to be found in Gram-positive enteric bacteria as well [Gwm, 20001. Some of the major 
mechanisms are reviewed below. 
1.8.1 Eftlux pumps 
Efflux of bile salts from the bacterial cytoplasm directly out of the cell is the best-
characterized mechanism of bile salt resistance. The secondary multidrug transporters AcrB 
and EmrB are involved in bile salt resistance in E. coli [Okusu et al., 1996; Lomovskaya & 
Lewis, 1992J. Similar efflu.x systems have been identified in other bacteria, including 
Salmonella typhimurium [Lacroix et al., 1996], Pseudomonas aeruginosa [Li et al., 1995] and 
Neisseria gonorrhoeae [Hagman et al., 1995]. 
Cholate resistance in L. /actis is mediated by an ATP-dependent multispecific organic anion 
transporter. This transporter does not, however, confer resistance to deoxycholate or cationic 
drugs, such as ethidium bromide and rhodamine 6G, which are typical substrates of other 
multidrug transporters such as LmrP and LmrA in L. lactis [Yokota et al., 20001. 
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1.8.2 Upopolysaccharide (LPS) 
The LPS of Gram-negative bacteria constitutes the majority of the outer leaflet of the outer 
membrane. While the lipid A portion of the LPS molecule anchors it in the membrane, the o~ 
antigen protrudes from the surface of the membrane and provides the major barrier to external 
compounds. A loss of the O-antigen creates a "rough" phenotype which results in a decreased 
resistance to bile as demonstrated in S. typhimurium [Prouty et al., 2002]. 
1.8.3 Bile salt hydro-lases 
In the intestine, the amino acid may be hydrolysed from the conjugated bile salt by bacterial 
enzymes known as bile salt hydrolases (BSHs). There are two main hypotheses as to the 
function of BSHs in enteric bacteria. One hypothesis is that bacteria that are able to 
deconjugate bile salts use the amino acid taurine as an electron acceptor. Evidence to support 
this hypothesis has been obtained for some Clostridium species [Gopal-Srivastava & 
Hylemon, 1988}. The second hypothesis states that BSHs decrease the toxicity of conjugated 
bile acids for bacteria. However, studies in lactobacilli have shown that BSH activity and 
resistance to the toxicity of conjugated bile salts are not related [Moser & Savage, 2001]. The 
addition of ionophore nigericin to BSH-producing Lactobacillus amylovorus, to dissipate the 
ApR, decreased the viability of the bacterium in the presence of conjugated bile salts. It has 
been hypothesised that after deconjugation, the deconjugated bile salts may be transported out 
of the cell using the PMF [Grill et ai., 2000]. 
1.8.4 Affect of bile on antibiotic resistance in bifidobaderia 
An interesting observation is that conjugated bile saIt-tolerant bifidobacteria have an altered 
antibiotic susceptibility pattern in the presence of these bile salts [Charteris et al., 2000]. The 
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bile salt oxgall diminished the intrinsic resistance of all strains of bifidobacteria to 
polymyxin B- and eo-trimoxazole,. while amino glycoside. resistance was-lost ~ extrinsic 
resistance of bifidobacteria to ampicillin, chloramphenicol, erythromcym, penicillinG, 
rifampiGin and. tetracycline was, als.o affected. by tbe.presence of Q;x.gall but it1 a strain~ and 
source-dependent manner [Charteris et al., 2000]. 
1.9 PROJECT AIMS 
The aim- of 1hisproject was. to investigate the molecular mechanisms respo~le . for the 
resistance against antibiotics and bile salts observed in bifidobacteria, and more specifically, 
to determine whether emux system; are involved in this resistance. 
This thesis describes the investigation into the intrinsic resistance of Bijidobacterium spp to a 
wide range.oftoxic compoUflds.and antibiotics. The question whether the bacteria are able to 
adapt to the presence oftoxic compounds to become more resistant, was also investigated. 
Evaluation- of the- functionality of putative transporter genes was investigated using 
complementation in the drug hypersusceptible Escherichia coli strain, KAM3 [Morita et al., 
1998} as well as bioinformatic analysis of the sequences and possible membrane topologies. 
In addition, analysis of the Bijidobacterium /ongum genome was used to identify putative 
efflux genes based on sequence similarity to known genes. Putative transporter genes were 
further investigated and characterized by way of efflux assays. 
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2.1 SUMMARY 
Five BiJidobacterium spp. were exposed to a range of antimicrobial agents. These included 
ethidium bromide, the bile salt sodium glycocholate and a range of antibiotics. Survival curves 
as well as intrinsic MIC values were determined in the presence of the antimicrobial agents. It 
was then determined whether pre-exposure to the antimicrobial agents resulted in an increased 
MIC value for the antibiotic tested (adaptive MIC value). The resistance profiles displayed a 
great amount of interstrain and interspecies variation in both the intrinsic and adaptive MIC 
values. Adaptation to at least one of the antimicrobial agents tested was observed in everyone of 
the bifidobacterial species. 
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2.2 INTRODUCTION 
There are many factors to consider in the selection of suitable bifidobacterial strains for use as 
probiotics. Survival in the human GIT, and safety concerns with the consumption of probiotic-
containing food products are important factors to consider. As mentioned in section 3 of 
chapter 1, the administration of antibiotic treatment directed at disease-causing bacteria can also 
compromise the survival of probiotic bacteria in the GIT. This can result in antibiotic-associated 
diarrhea. While resistance to antimicrobial agents may increase the survival rate of bifidobacteria 
in the human GIT, one of the aspects which should be studied is the safety and risks of 
acquisition of genes for the resistance to antimicrobial agents [Sullivan & Nord, 2002], especially 
if these bacteria are to be added in high numbers to food products. 
Minimum inhibitory concentration (MIC) values for a number of bifidobacterial strains have 
been reported [Charteris et ai, 1998; Lim et ai, 1993]. A great amount of interstrain and 
interspecies variation has been reported. It has been shown that some strains of bifidobacteria are 
resistant to up to 10 antibiotics [Yazid et ai., 2000]. Although bifidobacteria exhibit resistance to 
a wide range of antibiotics, little is know about the molecular basis for this resistance. There are 
also no studies investigating whether bifidobacteria are able to adapt in the presence of 
antibiotics. As reviewed in Chapter 1, active drug efflux can contribute to antibiotic resistance, 
possibly through the activity of multidrug transport proteins. There are a number of 
antimicrobial agents that are transported by such multidrug transport proteins. 
The mutagen ethidium bromide is a substrate common to many multidrug transporters [Miyamae 
et ai., 2001; De Rossi et al., 1998]. Ethidium readily crosses the membrane by passive diffusion 
and intercalates between the bases of DNA, thereby exerting its growth-inhibitory and mutagenic 
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effects. The presently characterized bacterial ethidium resistance mechanisms are all membrane-
located extrusion systems [Bolhuis et al., 1994]. Ethidium efflux systems have different 
specificities, but all confer cross-resistance to, or catalyze efflux of, unrelated compounds, like 
acriflavine, phosphonium ions, quaternary ammonium ions, aminoglycosides, rhodamine 6G and 
chloramphenicol [Bolhuis et al., 1994]. The physiological function of the ethidium extrusion 
systems could be related to a need for the organism to extrude toxic compounds encountered in 
the natural habitat, such as toxins produced by microorganisms or plants. Many of these 
compounds are both water and lipid soluble [Bolhuis et al., 1994]. 
The presence of ethidium bromide resistance can therefore be used as an indicator of the presence 
of a multidrug efflux system(s). As mentioned in section 1.7.3 of Chapter 1, the expression of 
several genes encoding multidrug efflux pumps is inducible by the drugs to which they offer 
protection [Zheleznova et al., 1999]. The ability of bacterial cells to become more resistant to 
ethidium bromide after pre-exposure to the compound, can also be evidence of the presence of a 
multi drug efflux system( s). 
The active efflux of bile salts such as sodium glycocholate is a common mechanism of bile salt 
resistance found in Gram-negative bacteria [Gunn, 2000] and has been described for the Gram-
positive L. lactis. Cholic acid is the main free bile acid produced by bile salt hydrolase (BSH) 
activity in the intestine and is one of the most abundant salts in bile [Schultz et al., 1991]. 
As mentioned in section 1.8.3 of Chapter 1, there is still much debate as to the role of bile salt 
hydrolases (BSH) in resistance to bile salts. The BSH isolated from bifidobacteria has been 
shown not to be induced by any extracellular factors including bile salts [Grill et al., 1995]. A 
change in the ability of bifidobacteria to withstand the effects of bile salts following pre-exposure 
to the bile salts would, therefore, not likely to be due to a change in the expression of BSH. 
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Since many multi drug transporters are regulated by the substrates they transport, an increase in 
the level of bile resistance following exposure to the toxic compound would indicate that such a 
transporter may be present. 
The aim of this study was, therefore, to ascertain whether the bifidobacterial strains studied were 
noticeably more resistant to certain antibiotics, ethidium bromide and/or the bile salt, sodium 
glycocholate. Also, whether the resistance profiles were similar to those reported in the literature 
since a great amount of interstrain and interspecies variation has been reported. In addition, it 
was of interest whether pre-exposure to antimicrobials would result in an increase in the 
resistance observed, since multi drug transporters are regulated by the compounds they transport 
[Baranova et al., 1999]. 
The comparison of MIC values can be difficult due to differing techniques and growth 
conditions. For this reason, the NCCLS has standardized techniques to determine MIC values for 
both aerobic and anaerobic bacteria. The MIC values in this study were, therefore, all determined 
using the same methodology and values were compared to those reported by the NCCLS. In this 
way, the values could be interpreted as to their significance. 
2.3 MATERIALS AND METHODS 
2.3.1 Bacterial strains, plasmids and culture conditions 
B~fidobacterium bifidum NCIMB 702203T (formerly NCFB 2203), Bifidobacterium breve 
NCIMB 702257T (formerly NCFB 2257), and Bifidobacteriul11 longum NCIMB 702259T 
(formerly NCFB 2259) were obtained from the NCIMB culture collection, UK. Bifidobacterium 
lactis DSM 10140T was isolated from freeze-dried yoghurt starter culture (Darleon Distribution) 
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(courtesy of Dr M. I. Trindade). B. bifidum strain W was obtained from a 6 day old baby 
(courtesy of Dr L. Brown, Food Technology, Cape Technikon). Bifidobacterial cultures were 
propagated anaerobically at 37°C in an anaerobic chamber (Forma Scientific, Model 1024), in an 
atmosphere of 5% H2, 10% C02 and 85% N2. Bifidobacteria were cultured in BYG medium 
(Appendix A.2). Glycerol stocks were prepared from cells grown in BHI broth (Appendix A.l) 
and stored at -70°C [Sambrook et al., 1989]. 
2.3.2 Resistance to ethidium bromide 
MIC values of Bifidobacterium spp to ethidium bromide were determined by a standard broth 
dilution method carried out using a two-fold dilution of the toxic compound [Koneman et al., 
1988]. Briefly, bifidobacterial strains grown for 16 h in BYG, were diluted to an OD600 of 
approximately 0.25 (Beckman DU64 spectrophotometer) and transferred to BYG broth 
containing ethidium bromide (Sigma) at concentrations ranging from] 2.5 to 400 IlM. Following 
incubation for 16 h, the OD600 of the culture was measured. The MIC values obtained are referred 
to as "intrinsic" values. Cells from the culture tube just below the MIC were diluted to an OD6oo 
of 0.25 and used to re-inoculate fresh BYG containing ethidium bromide concentrations in the 
same range as previously described. This second series was incubated under the same conditions 
and OD6oo readings taken. The MIC values obtained are referred to as "adaptive" values. The 
MIC values were defined as the lowest concentration of the toxic compound that inhibited 
growth. Complete experiments were completed in triplicate. 
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2.3.3 Resistance to sodium glycocholate 
Resistance of Bifidobacterium spp to sodium glycocholate (Difco) was investigated using the 
same methods as described for ethidium bromide except that plate counts were used instead of 
OD600 to evaluate growth. The pKa of cholate is 6.4, causing cholate precipitation in liquid 
media, thus making absorbance readings inaccurate. The appropriate dilutions were made in 
duplicate and the experiments were repeated in triplicate. 
2.3.4 Resistance to antibiotics 
Antibiotics were supplied as laboratory standard powders (all Sigma). Intrinsic MIC values of 
Bifidobacterium spp. to ampicillin, chloramphenicol, erythromycin, and tetracycline was 
determined by a standard broth dilution method carried out using a two-fold dilution of each 
antibiotic [Koneman et al., 1988]. Adaptation to the antibiotics was tested using a method 
adapted from Carsenti-Etesse et al (1999). Briefly, cells grown for 16 h were streaked onto 
gradient plates containing various concentrations of the antibiotic tested. At each passage, the 
sub-MIC culture (colonies nearest the inhibition zone) was selected and streaked onto other 
gradient plates containing higher concentrations of the antibiotic. This was repeated for 4 
passages and these MIC values obtained are referred to as "adaptive" values. A cell suspension 
was made from the adapted cells and inoculated into a broth dilution series of the antibiotic being 
tested. After 16 h, 10 III of the culture was spotted onto plates to detelmine cell viability. 
Gradient plates were not used until at least 4 hours after being made, to ensure diffusion of the 
antibiotic. Complete experiments were perfOlmed in triplicate. 
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2.3.5 Stability of adaptive resistance 
B. bifidum and B. [aetis cells adapted to tetracycline were tested for stability of the phenotype in 
the absence of the antibiotic. Pre-adapted cells were passaged 4 consecutive times on antibiotic-
free agar plates. A cell suspension was made from these cells and inoculated into a two-fold 
dilution series of the antibiotic being tested. The MIC values were measured as described in 
section 2.3.4. Complete experiments were performed in triplicate. 
2.4 RESULTS AND DISCUSSION 
2.4.1 Resistance to ethidium bromide 
In BYG, laboratory strains of bifidobacteria grew to an OD600 of approximately 1 after 16 h, 
while the natural isolate, B. bifidum strain W only grew to approximately 0.35. 
As shown in Figure 2.1 A, B. bifidum was able to grow in the presence of up to 50 11M ethidium 
bromide. Following exposure to the toxic compound it grew at 100 11M ethidium bromide. 
Neither B. breve nor B. [ongum showed any ability to resist the toxic affects of ethidium bromide, 
both showing intrinsic MIC values of 12.5 [.lM (Figure 2.1 B and D). 
Although B. [aetts displays a greater ability than B. breve to grow in ethidium bromide, it is not 
significantly resistant to the compound. Pre-exposure of B. [aetis to ethidium bromide did not 
result in an increased ability to resist the effects of this toxic compound, with the MIC value 
remaining at 50 !AM (Figure 2.1 C). 
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Figure 2.1 Resistance to ethidium bromide of the bifidobacteria as determined by the double dilution 
method. Growth was monitored by measuring the 00600 after overnight growth. The solid bars represent 
initial growth in ethidium bromide, and hatched bars growth following exposure to ethidium bromide. 
A: B. bifidum, B: B. breve, C: B. lclctis, 0: B. longum, E: B. bifidum strain W. All experiments were 
repeated in triplicate, with the variation in the 00600 expressed in the Y-error bars. 
Growth in the presence of ethidium bromide revealed that B. bifidum strain W possessed a higher 
level of intrinsic resistance than any of the other strains (Figure 2.1 E). The strain grew relatively 
well in ethidium bromide concentrations up to 100 ~M and weakly up to 200 11M. Similar results 
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have been described for Lactococcus lactis subsp lactis isolates expressing the multi drug 
transporter, LmrA, which were found to grow weakly in 200 )lM ethidium [Bolhuis et a!., 1994]. 
The growth did not appear to be significantly different following exposure to ethidium bromide. 
The MIC values reported are summarized in Table 2.1. 
As previously mentioned, all ethidium bromide resistance mechanisms known to date are 
membrane-located transport systems. The results reported here show that further investigation 
into the area of drug transporters in bifidobacteria is warranted. 
2.4.2 Resistance to sodium glycocholate 
Two different growth patterns were observed when unadapted bifidobacteria were grown in the 
presence of sodium glycocholate. B. bifidum and B. lactis grew in concentrations up to 14 % w/v 
(Figure 2.2 A and B). In both species, there was a rapid decrease in viability in growth of the 
bacteria in cholate concentrations up to about 4 %, followed by a gradual decrease in viability 
until no growth was observed. 
These observations suggest the presence of a subpopulation of cells that are more resistant to the 
effects of sodium glycocholate. In any population of bacteria, there is a small fraction of cells 
that are not killed by the presence of an antimicrobial agent. These cells are named ·'persisters". 
Persisters are not resistant to antimicrobial agents and do not exhibit increased MIC values 
[Lewis, 2000]. They are not mutants and their increased survival is not transferred to their 
progeny [Keren et al., 2003]. It has been shown that cells grown in the presence of antibiotics 
and then inoculated into fresh medium displayed the same growth pattern in the presence of the 
antibiotic tested as the original population. The growth of a sUbpopulation of B. hifidum and 
B. lactis up to 14 % w/v is, therefore, not due to the presence of persister cells. After pre-
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exposure to cholate, the growth pattern suggests that it is this subpopulation that grows up to 18 
% since the same level of growth is observed. 
A different pattern of growth was observed with B. longum and B. bifidum strain W (Figure 2.2 C 
and D). These species grew only in concentrations of cholate up to 0.4 %. The cessation of 
bacterial growth occurred quickly with no subpopulation able to resist the effects of the cholate. 
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Figure 2.2 Resistance to sodium glycocholate of the bifidobacteria as determined by the double dilution 
method. Growth was monitored by measuring viable cell count after overnight growth. The solid bars 
represent initial growth in sodium glycocholate (parent cells), and hatched bars growth after pre-exposure 
to low levels of sodium glycocholate (pre-exposed cells). A: B. bifuium, B: B. lactis C: B. longum, D: B. 
bifidum strain W. All experiments were repeated in triplicate, with the variation in the results expressed in 
the Y -error bars. 
Following pre-exposure to the compound, B. longum is able to grow in concentrations up to 
1.6 %. Cell viability decreased quickly as the non-exposed cells did, but growth occurred up to 
1.6 %. A slightly different growth pattern was observed with B. bifidum strain W. This strain 
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grew in up to 0.4 % as with B. longum. Following pre-exposure to cholate, the strain grows well 
in concentrations of cholate up to 0.8 %, after which viability decreases rapidly. This pattern of 
growth does not suggest the presence of a sUbpopulation of slow-growing cells [Keren et al., 
2003]. The MIC values reported are summarized in Table 2.1. 
2.4.3 Resistance to common antibiotics 
Antibiotics with a variety of structures and targets were tested. Gram-negative spectrum 
antibiotics, for example naladixic acid, were not used since they have been reported to be 
ineffectual against bifidobacteria [Lim et at., 1993]. The comparison of MIC values can be 
difficult due to differing techniques and growth conditions. For this reason, the NCCLS has 
standardized techniques to determine MIC values for both aerobic and anaerobic bacteria. In this 
way, the values could be interpreted as to their significance. According to the criteria set out in 
the NCCLS, MIC values can be divided into 3 interpretive categories, namely susceptible, 
intermediate and resistant (Table 2.2). 
2.4.3.1 ~-lactam 
As shown in Table 2.1, B. longum was the only species studied that displayed an adaptation to 
ampicillin exposure with a 2 fold increase in the MIC value of the adapted cells. The MIC 
values go from a susceptible category to an intermediate one following exposure to ampicillin 
[NCCLS, 1985] (Table 2.2). 
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TABLE 2.1 MIC values of antimicrobial agents tested against 5 bifidobacterial strains as 
determined by the double dilution method. An increase in the MIC value following growth in the 
antimicrobial is indicated in bold. The antimicrobial agents used were, ampicillin (Amp), 
chloramphenicol (Chi), erythromycin (Ern), Tetracycline (Tet), ethidium bromide (EtBr), and 
cholate. 
Bifidobacterium spp. 
Antimicrobial 
agent B. bifidum 
I B. breve B. bifjdum strain W B. lactis B. !ongum 
Amp (~glml) 
intrinsic 6.25 0.8 12.5 1.6 12.5 
adaptive 6.25 0.8 12.5 1.6 i 25 
I Fold increase 1 1 1 1 2 
: Chi (~glml) i 
intrinsic 16.25 1.6 12.5 3.12 3.12 
adaptive i 6.25 1.6 12.5 6.25 3.12 
Fold increase 1 1 1 2 1 
I E~(~~ml) 
0.8 0.8 ,0.8 1.6 • 0.8 . mtnnslC 
i adaptive 1.6 1.6 1.6 6.25 i 3.12 
Fold increase 2 2 2 4 4 
Tet(~ml) 
! 
intrinsic 12.5 10 25 6.25 6.25 
adaptive 1 50 10 100 6.25 6.25 
Fold increase 4 1 4 1 rt 
I E~Br ,<~~1) 
100 400 150 12.5 12.5 • mtnnsiC 
adaptive 200 400 50 12.5 
i 
12.5 
Fold increase 2 1 I 1 I 
cholate (% w/v) 
intrinsic 16 ND 16 0.6 0.6 
adaptive 20 ~D 20 1.8 1.8 
Fold increase 1.25 ND 1.25 3 3 
TABLE 2.2 Interpretive categories and MIC values against anaerobic bacteria. Adapted from 
;\,J' I C . f cr' I L b S d d (1985) . atlOna ommJttee or mIca a oratory tan ar s 
MIC (flglml) 
Antibiotic Susceptible Intermediate Resistant 
Ampicillin <0.5 ] >2 
Chloramphenicol 8 16 >32 
T etracyc line <4 8 >16 
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2.4.3.2 Gram-positive spectrum 
All species studied were able to adapt to increasing concentrations of erythromycin, with 
B. breve and B. Ion gum showing the greatest increase in erythromycin resistance (Table 2.1). 
Erythromycin has been reported to be the most active agent against bifidobacteria [Matteuzzi et 
al., 1983; Lim et al., 1993] but is not tested against anaerobic bacteria in the NCCLS. 
2.4.3.3 Broad-spectrum antibiotics 
B. breve showed a 2 fold increase in the MIC value following pre-exposure to chloramphenicol 
(Table 2.1). While B. lactis did not exhibit the ability to adapt to increasing concentrations of the 
antibiotic, it did display a highest the intrinsic MIC value to chloramphenicol than any of the 
other species studied. 
Chloramphenicol is generally effective against bifidobacteria [Matteuzzi et al., 1983]. Although 
there is strain variation, the bifidobacteria in this study can be classified as susceptible to 
chloraphenicol (Table 2.2). 
Following pre-exposure to tetracycline. both B. biJidum and B. lactis showed increased "\1.IC 
values to the antibiotic. The intrinsic resistance of B. biJidu111 to tetracycline can be classified as 
intermediate (Table 2.2). However, after exposure to the antibiotic, it becomes resistant to 
tetracycline. B. lactis showed the highest intrinsic "\1.IC value to tetracycline, and becomes 
greatly resistant to the antibiotic following pre-exposure with a 4 fold increase in the MIC value 
(Table 2.1). 
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In genera] B. bifidum strain W was the most susceptible to the antibiotics tested, while B. lactis 
showed the greatest ability to grow in the presence of the antibiotics tested. 
Importantly, the development of increased resistance to the various antibiotics and toxic 
compounds was highly reproducible upon repeat experimentation. 
2.4.4 Stability of adaptive resistance 
Both B. bijidwn and B. lac tis adapted cells did not lose their ability to withstand higher levels of 
tetracycline after repeated subculturing in the absence of the antibiotic. 
These findings are similar to those found in E. coli and Salmonella enterica cells adapted to 
detergents and antibiotics [Braoudaki & Hilton, 2004]. In that study, the adaptive resistance 
remained stable even after 30 days of passage in the absence of the detergents or antibiotics. 
2.5 CONCLUSIONS 
As mentioned in section 2.2, there is great interspecies and interstrain variation in the antibiotic 
profiles of bifidobacteria. This was once again displayed in the results presented in section 2.4. 
Adaptation to at least one of the antimicrobial agents tested was observed in everyone of the 
bifidobacterial species. A level of resistance below the cliteria as set by NCCLS would still be 
important, since even a small change in the susceptibility of a strain to any given antibiotic and/or 
antimicrobial may confer a growth advantage on it. 
Bifidobacteria are resistant to a number of different antimicrobials with different targets and 
modes of action. Antibiotic resistance in bacteria can be achieved via modification of the target 
of action, direct inactivation of the antibiotic, changes in the cell permeability and multidtUg dtUg 
efflux pumps. 
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The permeability of the bacterial cell envelope greatly influences the ability of antibiotics to enter 
the cell. However, in contrast to mycobacteria and Gram-negative microorganisms, most Gram-
positive organisms are not well protected from penetration by antibiotics [Lambert, 2002]. The 
thick peptidoglycan cell wall does not impede the movement of molecules less than of 50 kDa 
[Hogan & Kolter, 2002]. It is, therefore, unlikely that the resistance seen in this study is as a 
result of drug exclusion. 
The upregulation of multi drug efflux systems can provide cross-resistance to a number of 
antibiotics and/or antimicrobial agents [Levy, 2002]. In order to determine whether this is the 
case in bifidobacteria, future experiments should include the investigation as to whether pre-
exposure to one compound results in the increased resistance to another/other antimicrobial(s). 
Cross-resistance towards various antibiotics could be determined by streaking parent and adapted 
cells onto gradient plates each containing different antibiotics. Any differences observed would 
then be confirmed using the broth dilution method. This would allow the quick screening for 
cross-resistance. 
Of particular interest would be whether the cells pre-exposed to cholate displayed an altered 
range of MIC values to other antimicrobial agents. The bile salt, oxgall, has been shown to alter 
the susceptibility of bifidobacteria to all the antibiotics tested in this study [Charteris et al., 2000]. 
In addition, antibiotics designed against a spectrum of Gram-negative bacteria were found to be 
more effective against some bifidobacterial strains in the presence of bile salts. The mechanism 
by which this occurs is unknown. 
The ability of the Bijidobacteriunz strains tested to adapt to a number of unrelated antimicrobials 
was considered enough evidence to warrant further investigation into the possible molecular basis 
for the physiological characteristics observed and reported in this chapter. 
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3.1 SUMMARY 
A genomic library of Bifidobacterium lactis hosted in the hypersusceptible strain, Escherichia 
coli K.A..M3, was screened on tetracycline and ethidium bromide for colonies with increased 
resistance to either antimicrobial agent. Ten colonies were isolated which showed elevated levels 
of resistance to ethidium bromide. Sequence analysis was performed on all 10 recombinant 
plasmids. A putative ABC transporter system was identified and further characterized. Attempts 
to measure the ethidium efflux activity of the cloned transporter system proved unsuccessful in 
coli KAM3. The transporter was, therefore, subcloned into a Lactococcus lac tis expression 
system. Expression of the B. lactis ABC transporter system in a drug-sensitive L. lactis strain did 
not complement the phenotype. 
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3.2 INTRODUCTION 
The identification of genes encoding antimicrobial efflux proteins has been achieved using two 
main approaches. The first is the screening of a genomic library in a bacterial host for clones 
conferring an increased level of resistance to the host. This method has been used extensively in 
the identification of antimicrobial efflux proteins in many different bacteria, for example Vibrio 
parahaemolyticus [Morita et ai., 1998] and Enterococcus faecalis [Lee et ai., 2003]. With the 
advent of whole genome sequencing, complete genome sequences can be systematically analyzed 
and predicted antimicrobial efflux proteins can be identified. The function of the predicted 
transport proteins would then be confirmed through expression in a bacterial host. This method 
was used by Nishino and Yamaguchi (2001) to analyze 37 ORFs in Escherichia coli assumed to 
be antimicrobial efflux proteins by sequence similarities to known proteins in the databases. In 
both approaches a stable, drug- sensitive bacterial host is necessary. In this study, coli KAM3 
[Morita et al., 1998] was used for the screening of a Bifidobacterium lactis genomic library and 
the subsequent characterization of putative antimicrobial efflux proteins. This hypersusceptible 
strain has been used in the screening of bacterial genomic libraries [Morita et al., 1998], the 
expression of genes predicted to encode antimicrobial efflux proteins by sequence similarity 
[Nishino & Yamaguchi, 2001], and the characterization of putative efflux proteins by ethidium 
bromide transport assays [Morita et at., 1998J. E. coli KAM3 has even been used in the isolation 
of a multidrug efflux protein in Arabidopsis thaliana through the screening of a cDNA library 
[Li et al., 2002]. 
Morita et ai., (1998) constructed coli KAM3 from the K-12 derivative TGI (Appendix B). 
E. coli TG 1 cells were infected with the Mud(AmpR lac) phage in order to disrupt the 
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chromosomal acrAB genes, which code for the major multidrug efflux system in E. coli. The Mu 
phage region was then removed from the chromosome by heat induction at 42°C. The resulting 
cells were designated KAM3 and were shown to be sensitive to many drugs that are known 
substrates of the AcrAB system. The strain lacks a DNA restriction modification system making 
it ideal for the expression of heterologous genes. 
E. coli KAM3 is sensitive to the cationic dye ethidium bromide [Nishino & Yamaguchi, 2001]. 
As already mentioned, ethidium bromide is widely used to detect the presence and activity of 
multidrug transporter proteins. Ethidium bromide is also a useful substrate in the identification of 
antimicrobial efflux proteins as it can be used in the subsequent characterization of the protein. 
Ethidium bromide becomes fluorescent upon intercalation with polynucleotides, making the 
measurement of its influx/efflux int%ut of bacterial cells convenient to monitor. Other 
commonly used compounds include Hoescht 33342, the hydrophobic ester BCEF-AM and the 
anti-tumour drug, daunomycin. 
In Chapter 2, it was reported that B. lactis DSM 10140T was in general more resistant to a 
number of antimicrobial agents when compared to the other strains tested. This bifidobacterial 
strain was isolated from a dairy starter culture that is currently used in food products (Courtesy of 
Dr. M. I. Trindade]. Since the aims of the thesis were to investigate the presence of antimicrobial 
efflux systems in bifidobacteria, with the view to evaluate the safety of the administration of 
these probiotic strains, a commercial strain was chosen for further study. A genomic library of 
B. lactis DSM 10140 T was, therefore, used for screening and isolation of genes possibly 
encoding for antimicrobial efflux proteins. 
47 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
3.3 MATERIALS Al\1]) METHODS 
3.3.1 Bacterial strains, plasmids and culture conditions 
E. coli KAM3 served as the cloning and expression host for the introduction of recombinant 
plasmids [Morita et aI., 1998]. E. coli KAM3 was cultured in Luria-Bertani (LB) medium at 
37°C. Ampicillin (l00 llg/ml) was added to media for the growth of cells containing plasmid. 
Plasmids M13-derived Bluescript SK (pSK) (Stratagene, La Jolla, California, USA), and 
pEcoR251 [Zabeau & Stanley, 1982J were used for subcloning and sequencing. Plasmid 
pMT104, in which the EcoRI endonuclease has been insertional1y inactivated [Wehnert et aI., 
1990J, was used as a negative control vector in the characterization of recombinant plasmids. 
3.3.2 General recombinant DNA procedures 
Plasmid DNA was isolated by the alkali lysis method of Ish-Horowicz and Burke (1981) or with 
the QV\GEN Plasmid Midi Kit. All DNA modifications were performed according to standard 
procedures [Sambrook et al., 1989). All restriction and modifying enzymes were obtained from 
Roche Diagnostics and used according to general manufacturer's instructions. Competent E. coli 
KAM3 cells were prepared using the rubidium chloride method [Armitage et at., 1988] for use in 
subcloning. Electrocompetent E. eoli KAM3 cells were prepared using the method described by 
Tung and Chow (1995) for use in the screening of the B. laetts genomic library. Electroporation 
was carried out using Gene pulser apparatus (Bio-Rad laboratories, Richmond, Calif.) at 2.5 kV, 
200 n, and 25 flF. 
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3.3.3 Screening of the B. lactis genomic library 
A B. lactis Sau3A genebank (Courtesy of Dr. M. I. Trindade) was transformed into E. coli 
KAM3. Transformants were screened for increased resistance to ethidium bromide or 
tetracycline on LB agar (1.5 % w/v agar) containing ampicillin and ethidium bromide or 
tetracycline. Concentration ranges of 10 to 25 !-tglml ethidium bromide and 0.2 to 0.8 !-tg/ml 
tetracycline were used for the screening of the genomic library. Plasmid DNA was isolated from 
resistant colonies and used to retransform parental E. coli KAM3 cells to confirm the resistant 
phenotype. 
3.3.4 Nucleotide sequencing and sequence analysis 
Nucleotide sequences were determined by the fluorescent dideoxynucleotide chain termination 
method of Sanger et al. (1977) using the DYEnamic ET Dye Terminator Cycle sequencing Kit 
from MegaBACE (~101ecular Dynamics). All reactions were performed according to the 
manufacturer's instructions and cycle sequenced on a GeneAmp PCR system 9700 (Perkin 
Elmer, Applied Biosystems). The sequencing reaction products were analyzed on the 
MegaBACE 500 sequencer (AmershamPharmacia Biotech). The nucleotide sequences were 
analyzed using the MegaBACE 500 Sequence Analyser v2 and the DNAMAN software 
packages. Nucleotide and amino acid homology searches were performed, using the BLAST 
algorithm using the databases contained at NCBl [Altschul et al., 1997]. 
3.3.5 Characterization of antibiotic resistance profiles of putatiYe transporter proteins 
The MIC values for a range of antimicrobial agents were determined using the broth dilution 
method of Koneman et al. (1988). These included acriflavine orange (Merck) ethidium bromide 
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(Sigma), erythromycin (Sigma), SDS (Merck), sodium glycocholate (Difco), and tetracycline 
(Sigma). The experiments were repeated in triplicate. 
3.3.6 Transport assays 
The efflux of ethidium bromide by E. coli KAM3 cells containing a putative transporter protein 
was performed using the method adapted from van Veen et al. (1996). Exponentially growing 
E. coli KAM3 cells (culture volume of 100 ml) were harvested and washed twice with 50 mM 
potassium phosphate buffer containing 1 mM MgS04 pH 7.0 (KPi). The cells were resuspended 
to an OD600 of 5 in KPi and placed on ice. The cells were diluted 1110 in pre-warmed KPi for 
fluorescence measurements. Ethidium bromide was added to concentrations of 10 fAM to 50 fAM 
and allowed to accumulate. Glucose was then added to a concentration of 10 IIL.\1. To preload 
the cells with ethidium bromide, harvested and washed cells were incubated in the presence of 
ethidium bromide for 20 min at 37°C. The cells were washed and concentrated as described 
above. The cells were diluted 111 0 into pre-warmed KPi for fluorescence measurements. Glucose 
was added to a concentration of 10 mM. The fluorescence the ethidium bromide complex with 
polynucleotides was measured at excitation and emission wavelengths 500 and 580 nm, 
respectively (Bolhuis et at., 1994], For Hoescht 33342 (Molecular Probes), the compound was 
added to a concentration of 0.5 fAM to washed cells followed by the addition of glucose to a 
concentration of 10 mM. Hoescht fluorescence was measured at excitation and emission 
wavelengths 355 and 457 nm, respectively. All measurements were performed in the 
PerkinElmer Life Sciences model SOB fluorimeter with magnetic stirring holder at 37°C. 
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3.3.7 Expression of putative ABC transporter in Lactococcus lactis 
The ORF containing the putative ABC transporter was subc10ned in the lactococcal vector 
pNG8048E (NIZO Food Research, The Netherlands) (Appendix C). The ABC transporter gene 
was amplified by PCR from plasmid pEcoB4.23. Neol and Xbal restriction sites were introduced 
flanking the genes to enable cloning into pNG8048E, resulting in pNGABC. This plasmid 
contains the putative ABC transporter gene under the control of the nisin-inducible promoter, 
Pnis. Primers (ABC-F and ABC-R) used are shown in Table 3.1. PCR amplification using 
pEcoB4.23 as a template was performed with Taq Polymerase (0.25 U) (Supertherm) in a 50 ~l 
reaction mixture containing: 10 ng plasmid DNA; 0.5 mM of each of ABC-F and ABC-R; 0.5 
mM MgCh; and 200 ~M dNTP's. The amplification cycles were as follows: 96°C for 5 min; 25 
cycles of 96cC for 1 min, S2°C for 45 s, and 72°C for 1 min, and finally 72°C for 5 min. 
PCR products were purified using the High Pure PCR Product Purification kit (Roche). 
TABLE 3.1 Primers used for the subc10ning of ORF into pNG8048E. Restriction sites included 
are underlined. 
I Primer 
i name 
Primer sequence 
! ABC-F 
Ncol 
5' -AGTTCCATGGTGCATCGGCTGAGTTC-3' 
XbaI 
5' TTGAGATCTAGATTTAATGGCTGCTGGTAATG 3' 
I ABC-R 
: 
L. factis NZ9000 served as the cloning host for the introduction of recombinant plasmids. 
Electrocompetent Lactococcus lactis NZ9000 cells were prepared using the method described by 
Holo and Nes (1995). Electroporation was carried out using the Gene pulser apparatus (Bio-Rad 
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laboratories, Richmond, Calif.) at 2.5 kV, 600 n, and 25 1lF. L. lactis was grown at 30°C in M17 
medium (Difco) supplemented with 5 g glucose per litre and 5 IAg/ml chloramphenicol when 
necessary. 
3.3.8 Expression in Lactococcus lactis AlmrCD 
Lactococcus lactis /).lmrCD (Courtesy of J. Lubelski and R. van Merkerk, Department of 
Microbiology, University of Groningen) (Appendix B.l) was transformed with pNGABC. This 
lactococcal strain is sensitive to a number of antimicrobial agents including ethidium bromide 
and cholate due to the deletion of the ABC multidrug transporter LmrCD (J. Lubelski and R. van 
Merkerk, unpublished data). MIC values were determined by a standard broth dilution method 
carried out using a two-fold dilution of each antibiotic [Koneman et al., 1988]. NisinA (Sigma) 
was added to a final concentration of 10 ng/ml to induce the expression of the putative ABC 
transporter. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Identification and sequence analysis of potential transport proteins 
Screening of E. coli KAM3 transformed with the B. lactis genomic library on tetracycline did 
not yield any colonies with a greater level of resistance to the antibiotic. However, screening of 
the genomic library on ethidium bromide in E. coli KAM3 yielded 10 colonies exhibiting 
increased levels of resistance to the toxic compound (Table 3.2). Sequence analysis was 
performed on all recombinant plasmids (Table 3.2) and ORFs that showed sequence similarity to 
membrane extrusion systems were chosen for further investigation. Recombinant plasmid 
pEcoB 1.3 showed a low level of sequence similarity to a cell wall anchor domain protein found 
in B. longum NCC2705. Sequence analysis of the insert DNA of pEcoB1.5 revealed 4 putative 
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ORFs. These ORFs coded for the following putative proteins: a membrane protein with sequence 
similarity to colicin uptake proteins such as ToIA; a metalloendopeptidase; an acetyltransferase; 
and a putative molecular chaperone (Figure 3.1). Recombinant plasmid pEcoB 1.7 contained only 
one ORF on the insert D.NA, which showed sequence similarity to an aminopeptidase. Analysis 
of the insert DNA contained on pEcoB2.5 revealed the presence of 2 ORFs, one with similarity to 
a thioredoxin reductase, and the other to a chromosomal partitioning protein. Sequence analysis 
of the insert DNA of pEcoB4.5, revealed the presence of 4 ORFs, showing similarity to a 
glycosyltransferase involved in cell wall synthesis, two hypothetical proteins, and a 
transcriptional regulator. Since the sequences on recombinant plasmids pEcoB1.3, pEcoB1.7, 
pEcoB2.5, and pEcoB4.5 did not resemble any membrane located drug extrusion systems, they 
were not investigated further. 
Sequence analysis of the ORFs contained on recombinant plasmids pEcoB4.13, pEcoB4.18, 
pEcoB4.19 and pEcoB4.23 revealed that they all showed sequence similarity to regions of the 
same ABC transporter system from B. longum NCC2705 (Table 3.2; Figure 3.2). In addition, 
pEcoB4.23 contained sequence with similarity to a transcriptional regulator upstream of the 
putative ABC transporter. Recombinant plasmid pEcoB4.21 shows sequence similarity to a 
solute binding of an ABC transporter system in B. longum NCC2705. Drug/metabolite uptake 
systems but not efflux systems possess an extracytoplasmic solute binding receptor [Saier & 
Paulsen,2001]. No further work was therefore conducted on B4.21. 
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TABLE 3.2 Recombinant plasmids and the identity of the ORFs contained on the inserts as 
determined by sequence analysis. 
Recombinant DNA identity to genes lodged on NCBI Accession E 'EtBr 
plasmid database no. or value MIC 
reference (JlWml) 
pEcoBI.3 • LPXTG-motif cell wall anchor domain NP_977284 0.002 25 
I 
protein I 
pEcoBl.5 • colicin uptake protein ZP _00120427 2e-IO 25 
• metalloendopeptidase Gcp NP_696616 2e-50 
• acetyltransferase NP _696615 . 2e-32 
• putative molecular chaperone . ZP_00120471 i 5e-28 I 
pEcoBl.7 • aminopeptidase, PepN I NP_696360 4e-88 i 25 
I 
i I 
I pEcoB2.5 , • thioredoxin reductase I ZP _00151999 3e-07 125 
• chromosomal partitioning protein, ParA . NP_695834 2e-60 
pEcoB4.5 • glycosyltransferase involved In cell NP _695422 8e-38 25 
wall synthesis 
• hypothetical protein ZP_OO121655 ge-14 
• hypothetical protein NP _696762 2e-54 
I 
transcriptional regulator NP_599277 Ie-07 • 
pEcoB4.13 • 2C-methyl-D-erythritol 2,4- NP _696169 6e-09 25 
cyclodiphosphate synthase 
• ATP-binding protein of ABC NP_695373 3e-28 
transporter 
• ABC-type antimicrobial peptide NP _695374 8e-24 
transport component 
pEcoB4.l8 • ATP-binding protein of ABC NP _695373 3e-24 50 
transporter 
• ABC-type antimicrobial peptide I NP _695374 4e-18 
transport component 
pEcoB4.19 • A TP-binding protein of ABC NP_695373 le-21 25 
transporter 
• ABC-type antimicrobial peptide NP_695374 8e-28 
transport component 
pEcoB4.21 • Solute binding protein of ABC I NP _696166 3e-16 i 25 
transporter system I 
pEcoB4.23 • Transcriptional regulator NP_696075 2e-44 50 
• ATP-binding protein of ABC NP_695373 3e-25 
transporter 
• ABC-type antimicrobial peptide NP_695374 2e-55 
I , transport component 
pMTlO4 • Vector control Wehnert et ! 12.5 
I 
al., 1990 I i 
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3.4.1.1 Recombinant plasmid pEcoB1.5 
Further investigation was conducted on B 1.5 to determine whether the membrane protein 
contained in ORFI (Figure 3.1) was responsible for the elevated levels of ethidium bromide 
resistance. This was done through the deletion of the Bgl/I fragment on which ORFI occurs and 
the subcloning of the ORF into the high copy number plasmid pSK. 
The MIC values presented in Figure 3.1 indicate that it is indeed the membrane protein that 
confers the elevated levels of resistance to E. coli KAM3. When ORFI is more highly expressed, 
as in pSKTolr, the level of ethidium bromide resistance increases compared to the original 
construct pEcoB 1.5. 
ORFI OJ2 
8 a~ Recombinant EtBr MIC '" G ~. 8 -;:; i;~ :;; I~-l ,- ~ r-. ~~ ~ Plasmid (JI g/m I) ~-"-I 
~~ 
or, 
~. ,,!. ] i ~ ] ';j ~ ';j ';j ,:E 
r./~ ,:E 111 ,i! 111 -
I I f l I I I pEcoBl.5 25 
7150 
ORB DRF4 
1 TllObp 
pBgJdeJ 12.5 
pMTI04 12.5 
(vector control) 
pSKToi f 50 
pSK 12.5 
(vector control) 
FIGURE 3.1 Genetic organization of ORFs on recombinant plasmid pEcoB 1.5. Transcriptional 
polarities are indicated by arrows. Thick and thin lines represent the insert and vector 
respectively. Plasmid pSKToir contains a 1 kb BglII fragment from pEcoB 1.5 subcloned into 
pSK, so that ORFI is in same orientation as the lacZ promoter. The same 1 kb fragment was 
deleted to form pBglde\. The values presented are the ethidium bromide MIC values as 
determined by the broth dilution method. Plasmid pMT104 served as a negative control for 
pEcoR25 I-based plasmids, pEcoB 1.5 and pBgldel. Plasmid pSK served as a negative control for 
pSK-based plasmid pSKTolr . 
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Further sequence analysis of ORFI revealed that it showed low sequence similarity to the porin 
TalA which is involved in colicin uptake in coli (Table 3.3). Loss of porins is generally 
considered to be a mechanism by which Gram-negative bacteria become resistant to a wide range 
of antimicrobials [Nikaido & Vaara, 1985]. It is, therefore, unexpected that ORFI should confer 
ethidium bromide resistance to E. coli since the expression of porins should make the bacterial 
cell more susceptible to the influx of antimicrobial agents. 
TABLE 3.3 Percent identity and similarity of the predicted ORFs in pEcoB 1.5 to other proteins 
contained on the NCBI databases. 
IORF Homologous protein Accession Identity • Similarity I E value 
number (%) (o/c) 
1 B. longum, COG3064, ZP_OO120427 30 48 2e-lO 
membrane protein 
involved in colicin uptake 
2 B. longum, COG0533, NP _696616 73 81 2e-50 
metalloendopeptidase Gcp 
3 B. longum COG1214, ZP_OO12047J 48 57 5e-28 
putative molecular 
chaperone 
4 B. longum, COG0456 NP _696615 58 69 2e-32 
putative acetyltransferase i 
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3.4.1.2 Recombinant plasmid pEcoB4.23 
As mentioned previously, 4 of the clones isolated contained portions of the same ABC transport 
system. The sequences of all of the recombinant plasmids were compared and they were found 
to contain overlapping regions (Figure 3.2A). The overlapping regions all corresponded to ORFI 
of pEcoB4.23, thus indicating that it was this ORF that conferred elevated levels of ethidium 
bromide resistance to the host E. coli. As shown in Figure 3.2B, all the recombinant plasmids 
contain sequence similarity to regions of the ATP-binding protein, BL0154, and to the 
permease/transport component, BL0155, of an ABC transporter in B. Longum NCC2705. 
12 S ij ;:;! 
A ~ 'iii ~ 1;1 ~ ~ ~ 8 P< III <:< III ~ 
! (~ / I ORF2 ! ORFI ! I I • pEcuB4.23 
~ 
pEcuB4.13 
pEcuB4 .18 
pEcoB4 .19 
B ULO 153 I3LO 15-1 BLO 155 
~ I ,,,. 
FIGURE 3.2 A: Genetic organization of ORFs on plasmid pEcoB4.23. Transcriptional 
po larities are indicated by arrows. Thick and thin lines represent the insert and vector 
respecti vely. Regions of recombinant plasmids pEcoB4.13, pEcoB4.18 and pEcoB4.19 with 
sequence similarity to ORFI of pEcoB4.23 are shown. B: Organization of ABC transport system 
in B. longum NCC2705 with sequence similarity to recombinant plasmids. BLOI53 encodes a 
transcriptional regulator (yellow arrow); BL0154 an ATP-binding protein of an ABC transporter; 
BL0155 the permease component of an ABC transporter (blue arrows). Transcriptional polarities 
are indicated by arrows. 
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Unfortunately, none of the 4 clones appeared to contain the entire ABC transporter in spite of the 
resistance phenotype shown. It was decided to continue with the study using the clone 
pEcoB4.23. This clone contained the largest portion of the same ABC transporter system (Figure 
3.2A) and exhibited a high level of ethidium bromide resistance when compared to the other 
clones of the ABC transporter (Table 3.2). The ORFs contained on the insert DNA of pEcoB4.23 
were further analyzed for sequence similarity to known genes (Table 3.4), especially those 
contained in B. longum NCC2705, since the genome sequence of B. lac tis is not available on 
public databases. 
TABLE 3.4 Percent identity and similarity of the predicted ORFs in pEcoB4.23 to other 
proteins contained on the NCBI database. 
I ORF I Homologous protein Accession I Identity I Similarity E value 
I number i (%) . (o/c) 
1 B. longum, COG 1136: A TP NP_695373 84 92 3e-25 
binding protein of ABC 
transporter, BL0154 
B. [ongum, COG0577, ABC- NP_695374 34 47 2e-55 
type antimicrobial peptide 
i transport component, I 
BL0155 I 
2 B. longum, COG2865: NP_696075 31 50 2e-44 
predicted regulator 
containing HTH domain and 
uncharacteri zed domain 
shared with mammalian 
I I protein Schlafen, BL0898 
Transporters belonging to the ABC superfamily consist of 4 domains, two transmembrane 
domains/proteins and two cytopJasmic domains/proteins, containing the ATP-binding domain. In 
many bacterial ABC transporters, the 4 domains are contained in separate proteins whereas in 
eukaryotes, the domains are contained on a single polypeptide [Kerr, 2002; Lage, 2003]. 
58 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
In bacteria, a membrane domain can be fused to a cytoplasmic domain to form a "half-
transporter" . This is shown in Figure 3.3. These proteins form an active unit by homo- or 
heterodimerization. LrnrCD from L. lactis was the first heterodimeric ABC multidrug transporter 
to be characterized [Lubelski et al., 2004]. 
membrane domain AlP-binding domain 
\ . 
N-termmus 
outside cell 
cell membrane 
inside cell 
FIGURE 3.3 Membrane organization of a bacterial ABC multidrug transporter. The 
membrane/transport domain is fused to an A TP-binding cytoplasmic domain to form a "half-
transporter". The protein forms an active unit by homo- or heterodimerization. Conserved 
regions are shown in black [adapted from Putman et al., 2000] . 
ORFI appears to be a single polypeptide. In B. [ongum, BL0154 and BL0155 are closely 
positioned but separate ORFs. (Figure 3.2B). The ATP-binding and permease domains of ORFI 
were identified as well as the highly conserved Walker B motif and the ABC signature sequences 
of the ATP binding domain as (Figure 3.4). 
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1 MVHRLSSRRI ATQFGKASVM RAYFSTVSWX KKMTSTGPXS KGRXITVSXVF CSTXXPGGS 
Walker B 
61 AWXAYARALA KKPKLLLCDa PTGALDYETG ~LWDI CRTERMTVLIV'l'HNSALAPM 
121 AHKVIRFRSG KVTSQETNEH PVPDLAHVHA QIADSGSLHA EHGHARAVGSA FLLDTMRSG 
181 LHAWKPFLSI LIITMLGVAV LTGIYAGCRD TFAAANRFYR AQGLHDVQVIS TMGLTDADV 
241 DALRQVEGVE QAQGMRMIRV KVADGDGKQL NATLEEPASG SPAALDRPYV NEGWLPSKPG 
301 EVAVTAQFTH DTHKKLGDTV EVAADGEDDG THGLKIVGIV TDPSDLTNPG GYSAFRSSVT 
361 NDYTFYTAPD GIQRTFVKAD GTPlAAADPK VYGSIVLRLD DAENEDAFTA SYDDLVSGTV 
421 KRIENGVQAK REQARRNALV EEAQNKLDAE KKKAFDQIDA AQAKLDAQRR QLDDQLKQLD 
481 AQTAQIPVGV PEPAQLAEAQ RQWAAADTKL REAQQAIDTQ RNEAFSAFAA EQQKVDGIAT 
541 PRW 
FIGURE 3.4 Derived amino acid sequence of ORF identified as an ABC transporter carried on 
pEcoB4.23. Conserved residues are indicated in bold. Conserved regions are underlined . The 
ATP-binding domain is shaded in grey and the permease component of the protein in yellow . 
Analysis of ORF2 revealed that it belongs to the CRP family of cAMP regulatory proteins with a 
DNA-binding domain belonging to the catabolite activator protein family [Marchler-Bauer & 
Bryant, 2004]. As shown in Figure 3.2B , upstream of BLOI54, is BL0153 identified as a putative 
transcriptional regulator. This regulator may be involved in controlling the expression of 
BL0154 and BL0155 in B. longum NCC2705. This regulator, however, only showed 12 % 
sequence similarity to ORF2. The regulator on pEcoB4.23 shows 31 % identity at the amino acid 
level to another bifidobacterial regulator, BL0898 (Table 3.4) . This regulator is also upstream of 
a cluster of ABC transporter proteins on the chromosome of B. longum NCC2705 (Figure 3.5) . 
ORF2 may therefore, encode a transcriptional regulator of the ABC transport system contained 
on ORFI. 
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BL0898 BL0899 BL0900 BL0901 
500bp 
FIGURE 3.5 Position of the predicted ORFs BL00898, BL0899, BL0900 and BL0901 on the 
chromosome of B. longwn NCC2705. BL0898 encodes a transcriptional regulator (yellow 
arrow); BL0899 and BL0900 permease components of an ABC transporter ; and BL0901, the 
ATPase component of an ABC transporter (blue arrows) . Transcriptional polarities are indicated 
by arrows 
The components of the ABC transport system encoded by BL0899, BL0900 and BL0901 do not 
show high sequence similarity to ORF1 of pEcoB4.5 with 12 .65 %, 15 .58 % and 15.31 % 
respectively. The genes contained on the insert DNA of the recombinant plasmid and from 
B. lac tis are, therefore, not identical to those on B. longum, and may be the result of the 
recruitment of a regulator form a different operon as discussed previously in Chapter 1, 
Section 1.7.3. 
3.4.2 Characterization of antimicrobial agent resistance profile of B4.23 
B4.23 was tested against a number of antimicrobial agents (Table 3.5). It conferred elevated 
levels of resistance to the cationic dye acriflavine orange, the detergents sodium glycocholate and 
SOS, as well as to the antibiotic erythromycin . B4.23 does not, however, confer resistance to 
tetracycline. 
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TABLE 3.5 MIC values of B4.23 against various antimicrobial agents with reference to the 
1 MTI04 contro vector p~ 
MIC values 
Plasmid ethidium sodium SDS acriflavine erythromycin tetracycline 
name bromide glycocholate orange 
(Ilg/ml) (%) (%) (llg/m1) (Ilg/ml) (Ilg/ml) 
pMTI04 
12.5 0.25 0.005 6.25 1.6 0.5 
pEcoB4.23 
SO 1 0.01 SO 6.25 0.5 
3.4.3 Transport assays 
It was necessary to investigate whether the putative ABC transport system contained on B4.23 
conferred resistance to E. coli KAM3 through the active extrusion of ethidium bromide. This 
was attempted by using ethidium bromide transport assays. Ethidium bromide influx into the cell 
is convenient to monitor since it becomes fluorescent upon intercalation with polynucleotides. 
For the same reasons, Hoescht 33342 is commonly used in the characterisation of multidrug 
transporters. Hoescht 33342 becomes fluorescent upon intercalation in the lipophilic membrane 
as well as upon binding to polynucleotides [Shapiro & Ling., 1995]. 
In these experiments, the cells appeared not to be loaded sufficiently as they continue to 
accumulate ethidium bromide without ever reaching a maximum value (Figure 3.6 A), 
irrespective of the ethidium bromide concentrations used in the range of 10 50 flM. A similar 
problem was encountered when Hoescht 3342 transport was monitored (Figure 3.6 C). It was, 
therefore, decided to preload the cells with ethidium bromide to determine whether the addition 
of glucose would cause a decrease in the amount of ethidium bromide associated with the cell. 
However, as shown in Figure 3.6 B, the addition of glucose did not cause the efflux of ethidium 
bromide. 
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FIGURE 3.6 Measurement of ethidium bromide and Hoescht 3342 accumulation in de-
energized cells of E. coli KAM3 harbouring the control plasmid pMTI04 (pale blue line) and 
B4.23 (navy blue line) . A, Ethidium bromide was added to washed cell s.uspension to a final 
concentration of 10 11M. G~ucose was added to 10 mM at time points indicated. B, washed cell 
suspensions were pre-incubated in 20 J.l.M ethidium bromide and glucose was added to 10 mM at 
time points indicated . C, Hoescht 3342 was added to washed cell suspension to a final 
concentration of 0.5 /.lM. Glucose was added to 10 mM at time points indicated. Fluorescence of 
ethidium bromide and Hoescht 3342 was monitored over time. a.u., arbitrary units. 
Higher concentrations of the ethidium bromide (up to 50 fJM) and glucose (up to 50 mM) were 
used, but no change in the pattern was observed. An alternative protocol that could be used in 
future experiments, would! be to preload the cells in the presence of the uncoupler CCCP, 
followed by washing of the cells [Lee et al., 2003]. 
The rate at which the cells accumulated the compound did not change significantly whether the 
ABC transporter was present or not (Figure 3.6A and C). This could be due to the low level of 
63 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
expression of the gene, or the fact that the entire ATP-binding and permease domains are not 
contained on ORFl. Plasmid pEcoR251 is a low copy number plasmid and although the level of 
expression may be sufficient to observe an increased level of resistance to ethidium bromide, it 
may not be sufficient to measure using these assay techniques. In addition, the cells did not 
appear to be sufficiently de-energized. Therefore the addition of glucose would have no effect on 
the rate of ethidium bromide or Hoescht 3342 influx. The use of 2-deoxyglucose to de-energize 
the cells may have produced the desired effect. 
3.4.4 Expression of pNGABC in Lactococcus lactis /jJmrCD 
For the above reasons, the ORF containing the ABC transporter was subcloned into the 1. lac tis 
expression system pNG8048E. This allowed for gene expression under the control of the tightly 
regulated, inducible nisA promoter [de Ruyter et al., 1996], and since L. lactis is a Gram-positive 
bacteria, the membrane and cell wall structure is more similar to bifidobacteria than the 
previously used heterologous host, E. coli. 
The recombinant plasmid, pNGABC, contained the B. laetis ORF predicted to contain the ABC 
transporter under the control of the nisinA-inducible promoter contained on pNG8048E. The 
MIC values for pNGABC and pNG8048E were determined for cholate and ethidium bromide. 
However, no resistance was conferred on L. lactis !:llmrCD by pNGABC. This could be due to 
the incorrect functioning of the ABC transporter in L. laetis because of the truncated membrane 
domain. Alternatively, while bifidobacteria have a high G+C content, lactococci do not. The 
gene may, therefore, not have been expressed in 1. laetis. 
64 
U
iv
rsi
ty 
of 
Ca
pe
 To
wn
3.5 CONCLUSIONS 
Only one efflux system was identified in B. factis through the screening of a genomic library on 
both ethidium bromide and tetracycline. According to sequence analysis using TransportDB 
[www.membranetransport.org; described in Ren et al., 2004] there are at least 4 ABC mu]tidrug 
transporters and 20 secondary multidrug transporters in B. longum (Table 3.6). This may be an 
indication of the number of multidrug transporters present in B. zactis. In E. coli, 37 putative 
multidrug transporters were identified through sequence analysis of the entire genome sequence 
[Nishino and Yamaguchi, 2001]. 
It is, therefore, reasonable to assume that the method used in this study was ineffective in 
identifying the vast number of multidrug transporters present in bifidobacteria. This could be due 
to a number of factors. Firstly, as already mentioned, the expression of genes from Gram-
positive bacteria in a Gram-negative host is not ideal. This is especially true for membrane 
proteins. The difference in cell membrane structure could result in the incorrect functioning of an 
expressed gene. In addition, bifidobacterial DNA has a high G+C content which may lead to the 
genes contained on the recombinant plasmids not being expressed in E. coli. E. coli KAM3 has, 
however, been used to identify drug transporters in a number of organisms including Arabidopsis 
thaliana [Li et at., 2002]. It was, therefore, a reasonable strategy. 
Another reason for the failure to identify more multidrug transporters could be that other 
antimicrobials should have been used in the screening. These could include chloramphenicol and 
erythromycin. Bifidobacteria were able to adapt these antibiotics as shown in Section 2.4.3 of 
Chapter 2. 
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TABLE 3.6 Putative multi drug transporters in B. [ongulIl NCC2705 as predicted using TranspOItDB [www.membranetransport.org] with gene 
annotations as on the NCBI database. 
-_ ....... __ .... -
ATP-de endent transporter~ --, 
The ABC superfamily 
f Seco;;dary transporters 
SMR 
MFS 
BLO 162 probable permease protein of ABC transporter system 
BLO 163 ABC-type multidrug transport system, ATPase and permease components 
BLO 179 probable permease protein of ABC transporter system 
BLO 180 probable permease protein of ABC transporter system 
BLI 041 ATP binding protein of ABC transporter 
BLI 766 I ATP-binding protein of ABC transporter 
BLI 767 ABC transporter, ATP-binding transmembrane protein 
~~0575 
BLI406 
BLI444 
1566 
BL0037 
BL025 I 
BL0332 
BL0475 
BL068 I 
BL0919 
BL0920 
BLI270 
BL1303 
BLI699 
narrowly conserved hypothetical protein 
possible integral membrane protein with duf6 
widely conserved hypothetical transmembrane protein with duf6 
~onserved hypothetical transmembrane protein with duf6 
probable efflux-type transporter 
widely conserved hypothetical transport protein 
narrowly conserved hypothetical protein 
hypothetical membrane protein with unknown function 
conserved hypothetical transport protein 
possible efflux transporter protein 
possible efflux transporter protein 
______ -+I-=BLI703 
MATE 
hypothetical transmembrane protein possibly involved in uptake or efflux 
hypothetical transmembrane protein possibly involved in transport 
hypothetical transmembrane protein possibly involved in efflux transport 
hvoothetical membrane orotein in maior facilitator transoorter famil 
BL0432 I hypothetical protein in upfOO 13 
BL0842 . hypothetical protein 
BL0844 widely conserved hypothetical transmembrane protein with dufO 13 
~ I BLI()82 conserved hypothetical transmembrane protein in upfOO 13 
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For the above reasons, a more targeted approach may prove more successful in the identification 
and characterization of muhidrug transporter genes in bifidobacteria. Although B. longum is not 
the predominant species of bifidobacteria used commercially, studies in this species could be 
applied to commercially used strains. A PCR approach to the cloning and substrate 
characterization of the putative transporters in E. coli KAM3 such as that used by Nishino and 
Yamaguchi (2001) may yield better results than those presented in this chapter. Thj s approach 
would also circumvent the problem of the incomplete genes being cloned as occurred with 
recombinant plasrruds pEcoB4. 13 , -B4.l8, -B4.19 and -B4.23. 
It is, however, important to note that the gene cluster on B. longwn NCC2705 that showed 
sequence similarity to the ABC transporter cloned from B. lactis, namely BL0154 and BL0155, 
are not annotated as possible antibiotic extrusion systems. This illustrates that while genome 
analysis may identify many putative drug transporters, those with a novel signature sequence or 
membrane organization would be missed. Identification of drug efflux systems through 
functional complementation is therefore still a valid approach and more likely to identify novel 
drug transporters if they exist in Bifidobacterium spp. 
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4.1 SUMMARY 
The publication of the Bifidobacterium longum genome on public databases has allowed for the 
identification of putative efflux genes based on sequence similarity to known genes. Using this 
method, a putative sodiumlbile symporter was identified in B. longum. The gene, BL1102, was 
isolated using a peR amplification approach. BL1102 was subcloned and expressed in 
Escherichia coli KAM3, an efflux negative mutant. The construct was shown to confer greatly 
elevated levels of resistance to sodium glycocholate (16 fold). Energy-dependent efflux of the 
bile salt was demonstrated using radiolabelled cholate. 
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4.2 INTRODUCTION 
For a bifidobacterial strain to be an effective probiotic it must be able to survive inhibitory host-
produced substances such as bile salts [Margolies et ai., 2003]. 
The physiological property of bile resistance is a complex one. Enteric Gram-negative bacteria 
are inherently resistant to bile through the basic, asymmetric structure of their outer membranes 
which significantly reduces the diffusion of hydrophobic compounds, such as bile acids, across 
the outer membrane [Nikaido & Vaara, J 985]. Since the protection conferred by the outer 
membrane is only partial, the bacteria also express transport proteins that extrude bile acids. 
These have been identified in many Gram-negative bacteria such as Escherichia coli [Okusu et 
at., 1996] and Salmonella typhimurium [Lacroix et ai., 1996]. 
Studies in S. typhimurium have revealed the presence of bile-salt-mediated induction of 
antimicrobial and bile resistance through the regulation of several different genes [Prouty et al, 
2004]. DNA microarray analysis showed that the marRAB operon was bile-activated. In 
addition, experiments involving the fusion of the acrAB promoter to the luc gene, showed that the 
AcrAB efflux pump is also regulated by bile. The marRAB operon is involved in multidrug 
resistance in a number of bacteria including E. coli and S. typhimurium [reviewed in Alekshun & 
Levy, 1999]. MarR encodes a DNA-binding protein that functions as a repressor of the mar 
operon. MarA encodes a DNA-binding protein that is a positive global regulator, while MarB 
encodes a small protein of unknown function. The activation of marAB has been shown to 
increase levels of expression of the drug transport proteins AcrAB-ToIC [reviewed in Alekshun 
& Levy, 1997]. A model was proposed by Prouty et al. (2004) linking the effect of bile on 
transcriptional regulation in S. typhimurium. In the model, bile salts enter the cell and 
deoxycholate interacts with MarR, inhibiting its binding to the mar operator. Although it was 
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initially hypothesized that this led to an increased the level of acrAB expression, and hence 
increased levels of bile resistance, this was found not to be the case. The regulation of the mar 
operon must, therefore, affect currently unknown genes that playa role in resisting the effects of 
bile. Concurrently, bile regulates acrAB independently of marRAB. The increased expression of 
acrAB would then allow the efficient removal of bile acids from the bacterial cell. 
Less is known about the molecular basis for bile resistance in Gram-positive bacteria. It is likely 
that it is due to more than one physiological property of the bacterial cell. For example, in 
Listeria monocytogenes, the construction of a mutant bank allowed for the identification of 5 
gene loci involved in bile resistance. These included a gene involved in capsule synthesis, a 
putative MFS transporter and a putative transporter of the glutamate decarboxylase acid 
resistance system [Begley et al., 2002]. 
As mentioned in Chapter 1, Section 1.8.3, bile salt hydrolase (BSH) has been postulated to be 
involved in bile resistance in Gram-positive enteric bacteria. BSH activity has been detected in 
bifidobacteria and this genus possesses higher BSH activity than other bacterial groups [Kim et 
al., 2004]. It is still unknown what benefit BSH activity affords the cell. A study by Grill et al. 
(2000) compared a Lactobacillus amylovorus strain with decreased conjugated bile salt hydrolase 
(CBSH) activity with the wild type strain. They found that the growth rate of the mutant in the 
presence of bile salts was affected more than the wild-type strain, but that bile was more toxic for 
the wild-type strain. De-energization experiments suggested that the chemical potential of 
protons (Z~pH) was involved in the bile salt resistance of lactobacilli. They hypothesized that 
after deconjugation, the deconjugated bile salt may recapture a proton and be exported out of the 
cell. The transport would then decrease the Z~pH and enhance the resistance to bile salts. In this 
way, a strain with a more active CBSH would survive better in the intestinal tract. 
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Moser and Savage tested the hypothesis that in lactobacilli, BSH protects the cells that produce it 
from the toxicity of conjugated bile salts [Moser & Savage, 2001]. They assayed 49 strains of a 
number of Lactobacillus spp. for the ability to express BSH activities and their ability to resist 
effects of the conjugated bile acid taurodeoxycholic acid (IDCA). They found that the capacities 
of lactobacilli to resist the toxicity of TDCA and the capacities of to express IDCA hydrolase 
and CA hydrolases were independent properties. 
BSH isolated from bifidobacteria has been shown not to be induced by any extracellular factors 
including bile salts [Grill et al., 1995]. However, in this study it was found that B. longum was 
able to withstand higher concentrations of bile salts following pre-exposure to the bile salts 
(Chapter 2, Figure 2.2). This suggested that B. longum may contain a transporter capable of 
extruding bile acids. 
The publication of the B. longum NCC2705 genome on public databases [Schell et aI., 2002] has 
allowed for the identification of putative efflux genes based on sequence similarity to known 
genes. It was, therefore, decided to investigate whether any of the open reading frames (ORFs) 
identified in the genome encoded for a transport protein capable of extruding bile acids which 
might confer protection to bifidobacteria. 
72 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
4.3 MATERIALS AND METHODS 
4.3.1 Nucleotide sequence and analysis 
Nucleotide sequences were detennined by the fluorescent dideoxynucleotide chain termination 
method of Sanger et al. (1977) using the DYEnamic ET Dye Terminator Cycle sequencing Kit 
from MegaBACE (Molecular Dynamics). All reactions were performed according to the 
manufacturer's instructions and cycle sequenced on a GeneAmp PCR system 9700 (Perkin 
Almer, Applied Biosystems). The sequencing reaction products were analyzed on the 
MegaBACE 500 sequencer (AmershamPharmacia Biotech). The nucleotide sequences were 
analyzed using the MegaBACE 500 Sequence Analyser v2 and the DNAMAN software 
packages. Nucleotide and amino acid homology searches were performed, using the BLAST 
algorithm using the databases contained at NCBI [Altschul, et aI, 1997]. 
4.3.2 Bacterial strains, Plasmids and Culture Conditions 
Bifidobacterium longum NCIMB 702259T were obtained from the NCIMB culture collection, 
UK. Bifidobacterial cultures were propagated anaerobically at 37°C in an anaerobic chamber 
(Forma Scientific, Model 1024), in an atmosphere of 5% H2, 10% CO2 and 85% N2• 
Bifidobacteria were cu1tured in BYG medium (Appendix A.2). 
E. coli KAM3 [Morita, et ai., 1998] served as the cloning and expression host for the introduction 
of recombinant plasmids. E. coli KAM3 was cultured in Luria-Bertani (LB) medium at 3rc. 
Ampicillin (l00 lAg/ml) was added to media for the growth of cells containing plasmid. Plasmid 
M13-derived Bluescript SK (pSK) (Stratagene, La Jolla, CA) was used for subcloning and 
sequencing. 
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4.3.3 DNA Extraction and General Recombinant D~A Procedures 
Isolation of chromosomal DNA was performed as described by Trindade et al. (2003). 
Plasmid DNA was isolated by the alkali lysis method of Ish-Horowicz and Burke (1981) or with 
the QIAGEN Plasmid Midi Kit. All DNA modifications were performed according to standard 
procedures [Sambrook et ai., 1989]. All restriction and modifying enzymes were obtained from 
Roche Diagnostics and used according to general manufacturer's instructions. Competent E. coli 
KAM3 cells were prepared using the rubidium chloride method [Armitage et at 1988]. 
4.3.4 peR of putative cholate transporter, BLII02 
In order to isolate ORF BLl102 (Bifidobacterium longum NCC2705, Genbank: AE014295, 
NCB I database), primer ctrans-F was designed to 317 bp upstream of the putative start codon and 
ctrans-R to 116 bp downstream of the putative stop codon. Restriction enzyme sites were 
introduced where necessary to assist subcloning into pSK (Table 4.1). PCR amplification using 
bifidobacterial DNA as a template was performed with Taq Polymerase (0.25 U) (Supertherm) in 
a 50 III reaction mixture containing: 50 ng chromosomal DNA; 0.5 mM of each of ctrans-F and 
ctrans-R; 0.5 mM MgCh: and 200 IlM dNTP's. The amplification cycles were as follows: 96°C 
for 5 min; 25 cycles of 96cC for 1 min, 56°C for 45 s, and ncc for 1 min, and finally 72°C for 5 
min. PCR products were purified using the High Pure PCR Product Purification kit (Roche). 
TABLE 4.1 Primers used for the isolation of BLlI 02. Base pair changes to introduce restriction 
sites are indicated in bold. Restriction sites included are underlined. 
Primer name I Primer sequence I 
ctrans-F EcoRI . 
5' - AGCTGAA TTCGCGCAACAGG - 3' 
. ctrans-R KpnI 
5' -ACGCCCGGTACCTCAATCG- 3' 
I 
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4.3.5 Determination of resistance to sodium glycocholate 
Recombinant plasmid, pSKctrans, was expressed in E. coli KAM3. The MIC values for sodium 
glycocholate (Difco) were determined using the broth dilution method of Koneman et al. (1988). 
4.3.6 Effiux of e4C] cholate 
The method used was based on that of Yokota et al (2000) using [carboxyl-14C] cholic acid (New 
England Nuclear Corp). Exponentially growing E. coli KAM3 cells (culture volume of 100 ml) 
harbouring pSK or pSKctrans, were harvested and washed once with 50 mM potassium 
phosphate buffer containing 1 mM MgS04 pH 7.0 (KPi). The cells were resuspended to an 
OD6oo of about 20 and de-energized by incubation in the presence of 10 mM 2-deoxyglucose 
[Sigma] at 37°C for 30 min. The cells were then washed three times with KPi buffer and 
resuspended to an OD600 of about 4 in the same buffer. Aliquots (1.94 ml) of this cell suspension 
were placed at 37°C. To preload the cells with cholate, 40 111 of 5.8 mM e4C] cholate 
(16 mCi/mmol) was added so that the final cholate concentration was 0.116 mM. After 
incubation at 37°C for 30 min, the aliquot was split in two, and glucose was added to one of the 
aliquots to a final concentration of 10 mM. At various time intervals, the amount of C4C] cholate 
associated with the cells was determined using the rapid-filtration method. Briefly, 100 111 
aliquots were removed and filtered over 0.45-!1M-pore-size cellulose-acetate filters. The filters 
were washed twice with 2 ml of ice-cold 100 mM LiCI in 100 mM KPi, pH 7.0. The 
radioactivity retained on the filter was measured in a liquid scintillation counter after the addition 
of 2 ml of the scintillation cocktail (Emulsifier Scintillator Plus, Perkin Elmer). The background 
level of radioactivity associated with the filter (obtained from control incubations without cells) 
was subtracted from all readings. The amount of radioactivity associated with each aliquot was 
calculated for each experiment and used to calculate the counts per minute (cpm) per mM of 
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cholate. The results were expressed as nmol cholatel [,lg protein. During each experiment, 
samples were taken in triplicate. The entire experiment was also performed in triplicate. 
4.3.7 Protein quantitation 
The cell suspension was boiled for 10 min in 1 N NaOH. The protein concentrations were 
determined using the DC Protein Assay Kit (Bio-Rad) according to the manufacturer's 
instructions with BSA as the standard. 
4.4 RESULTS AND DISCUSSION 
4.4.1 Bioinformatic analysis of Bifulobacterium longum genome for candidate genes 
Since the release of whole genome sequences onto public databases, function predictions based 
on sequence similarity to other genes of known function have been attempted. This has led to the 
identification of many putative transport genes. Using the annotation on the NCBI database, 
ORFs encoding putative transport genes were identified. From this group of genes BL11 02 was 
identified as a possible candidate bile transport gene. ORF BL11 02 is annotated as a probable 
sodium dependent transporter, possibly for ileal bile acids. Translation of the ORF yielded a 
predicted 353 aa protein. Using the blastp program, BL1102 was found to be similar to a number 
of sodium dependent (Na+) bile transporters as shown in Figure 4.1 and Table 4.2. Further 
analysis of BL11 02 using the NCBI website revealed a number of conserved domains as shown 
in Table 4.3 [Marchler-Bauer & Bryant, 2004]. 
76 
U
ive
rsi
ty 
of 
C
pe
 To
wn
8. 10n 
S.the 
S.mut 
L.mes 
O.ihe 
8.sub 
P. flu 
N.men 
8.lon 
S.the 
S.mut 
L.mes 
O. ihe 
8.sub 
P. flu 
N.men 
8.10n 
S.the 
S.mut 
L.mes 
O. ihe 
8.sub 
P. flu 
N.men 
8.10n 
S.the 
S.mut 
L.mes 
O. ihe 
8.sub 
P. flu 
N.men 
B.10n 
S.the 
S.mut 
L .mes 
O. ihe 
B.sub 
P. flu 
N.men 
B.lon 
S .the 
S.mut 
L.mes 
O. ihe 
B.sub 
P . flu 
N.men 
PGTTLATTKVGNLSAVS 
· ...... SGFSI IAPHI 
· ...... SLFT ISSYIT 
· . . . .. . AWFLGLKGAI 
· . .... . DTFKlAGPYI 
KIY.PKGFRY 
SS NHD~EIHWDSDNGEKGSAKSTVSAAHPFDADKAAKVAA 
SS NH ......... s .... K ... KS ....... . ....... . H. 
SS H ......... S .... . .. . QS .. . .. H.L.TER .. K . . . 
Ar SKKG ISIIQ . . EKVENLG . ... . .... . ....... . . . 
NHTI PD ........ . .. . . . ....... . . ... ..... . 
Ar 
ST 
Ar 
SKKV .. K . . QAGSKSSNLSL ... . ...... .. .... . . . 
RMSE DSETLAQQAAD .... . .. . .. ... .... . .... . 
G KKP . . .................. . .... . .... . 
58 
58 
58 
65 
58 
58 
58 
58 
119 
119 
119 
126 
119 
119 
119 
119 
183 
IHSI 183 
183 
190 
182 
182 
182 
182 
245 
245 
245 
2 52 
244 
244 
244 
244 
308 
300 
300 
307 
301 
299 
299 
301 
353 
312 
316 
320 
324 
321 
321 
315 
FIGURE 4.1 Multiple sequence alignment of the putative bile transporter BL1102 with other 
predicted Na+ !bile transporters. Sequences included are from the following organisms: 
B. longum (B. Ion), Streptococcus thennophilus (S . the), Streptococcus mutans (S. mut), Leuconostoc 
mesenteroides (L. mes), Oceanobacillus iheyensis (0. ihe), Bacillus subtilis (B . sub), Pseudomonas 
fluorescens (P. flu), and Neisseria meningitides (N. men). Sequence accession numbers are supplied in 
Table 4.2). Identical amino acids are shaded in green, and similar amino acids are shaded in blue 
and yellow. 
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TABLE 4.2 Analysis of genes with sequence similarity to BLlI02 
c---~~~~~ 
Accession Species Description 
no. 
-YP _141686. I Streptococcus thermophilus LMG bile acid:Na+ symporter (BASS) family 
18311 protein 
NP_72 1034. I Streptococcus mutans UA 159 putative sodium-dependent transporter 
ZP _00063561.1 Leacom)SloC mesenteroides predicted Na+-dependent transporter 
NP _691915.1 Oceanobacillus iheyensis sodium-dependent transporter 
HTE83 I 
CAB13827.1 Bacillus subtilis subsp . subtilis str. probable sodium-dependent transporter 
168 yocS 
ZP _00262238.1 Pseudomonasfluorescens PfO-J predicted Na+-dependent transporter 
NP _273747.1 Neisseria meningitidis MCS8 transpOlter 
------ ------- -------
TABLE 4.3 Analysis of conserved domains within BLl102 
Acces 
gnJiCD 
gnilCO 
gnllCO 
gnilCO 
gnllCD 
;ion no. 
01210259 
012288 
DI I 0666 
0110548 
0126102 
----------
classification description 
COG0385 predicted sodium-dependent transpOlter 
pfamOl758 Sodium bile acid symporter family (SBF) 
COG0798 Arsenite efflux pump (ARC3); related permeases 
COG0679 predicted permeases 
pfam03547 auxin efllux carrier 
identity 
(%) 
59 
57 
51 
44 
44 
44 
41 
nment 
residue) 
9 
199 
2 
54 
47 
positive E value 
(%) 
73 e-I05 
73 e-I02 
68 3e-85 
62 6e-70 
61 7e-69 
61 e-66 
59 2e-65 
score E value 
220 e-58 
104 2e-23 
62.9 6e-11 
47.2 3e-6 
44.5 2e-S 
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Proteins belonging to the sodium bile acid symporter family (SBF) are found in bacteria, yeast, 
plants and animals such as mice and humans, with over 50 members already identified 
[Hagenbuch & Dawson, 2004]. The size of ORF Bl1102 is consistent with other members of 
the family, for example the human gene SLCJOAl, which is a 349 aa membrane protein. 
Analysis of the membrane topology revealed the presence of 9 TMS (Figure 4.2) 
[www.cbs.dtu .dkJservicesffMHMM centre for biological sequence analysis, Technical 
University of Denmark, prediction of transmembrane helices]. Computer modeling of other 
members of the family has suggested between 7 and 9 TMS [Hagenbuch & Meier, 1994]. 
However, experimental data derived from translation/insertion scanning, alanine insertion and 
glucosylation site mutagenesis, supports a 9 TMS topology [Hallen et at., 2002]. 
1 .2 ..----,...-----.,...----~----.----__r_------,----__" 
0.8 
.~ 
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..Cl 
a 
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FIGURE 4.2 Membrane topology of BLl1 02. The transmembrane helices are represented by 
the red lines, while the orientation is marked by the blue (inside) and pink (outside) lines . 
The position of BLl1 02 on the chromosome of B. longum was investigated to determine whether 
any genes in the flanking regions could also be involved in bile resistance (Figure 4.3). Analysis 
revealed that BLl102 is not part of an operon . Analysis of BLl101 did not result in any 
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significant sequence similarity to any known protein. Upstream of BL1102 is the tRNA-His 
sequence. It was, therefore, decided to isolate only BU1 02 for further characterization. 
~ ~ §:§ 8 ~ § ~ ~ '>D N "'" N N .,., S t; 000- ~ :::- <') :::-:e ~ ~ :::- :::-
~ ]~ ] ~ ~ 
-.:; C2 
Ob Ob '" 0 z '" c:I 0.. :x: c:I :x: 0.. 0.. c:I u.J 
> ~ 1 \ 1 1 ! ! 1 ! ' .. --i BUIOI BLlI02 
hypothethical protein Na dependent transporter of bile IRNA·His 
200bp 
FIGURE 4.3 Genetic organization of BL1102 and flanking regions. Transcriptional polarities 
are indicated by arrows. Posi tion 1 corresponds to 24411 of the genome sequence. 
4.4.5 PCR and subcloning of BLl102 
PCR amplification of the B. longum chromosomal region coding for BLI102, using ctrans-F and 
ctrans-R, yielded the expected 1.38 kb fragment. The fragment was subcloned into pSK and 
sequencing revealed that the correct DNA fragment had been cloned. The resulting plasmid was 
named pSKctrans (fholate transporter). 
4.4.6 MIC values of E. coli KAM3 (pSKctrans) to sodium glycocholate 
E. coli KAM3 harbouring the plasmid pSK, had a MIC value of 0.25% to sodium glycocholate 
whereas pSKctrans increased this value to 8% . Taken together with the sequence analysis, this 
suggested that a bile transporter had indeed been isolated. 
80 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
4.4.7 Efflux of [14C] cholate 
In order to investigate whether pSKctrans conferred resistance to bile through the active efflux of 
the compound, assays were performed using radiolabelled cholate. This would exclude the 
possibility of pSKctrans conferring bile resistance through the decreased influx of bile. The 
amount of cell-associated [14C] cholate was monitored in E. coli KAM3 harbouring pSKctrans or 
the control vector pSK. De-energized washed cell suspensions were used with/without the 
addition of glucose as an energy source. The results are shown in Figure 4.4. 
6 
A 
glucose 
1 
------ ---
"f------------t -___ _ 
........ - ....... 
3D 32 36 38 40 42 44 46 48 50 
time (min) 
B glucose 
1 ......... -. -
30 32 34 36 38 40 42 44 48 50 
time (min) 
FIGURE 4.4 Energy-dependent extrusion of [14C] cholate in E. coli KAM3. After the cells were loaded 
with cholate (solid lines), glucose was added to a final concentration of 10 mM at the time point indicated 
by the arrow. The amount of cell-associated cholate was subsequently measured over time (dotted lines). 
E. coli KAM3 , (A) pSKctrans (blue), (B) pSK (red). 
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In the absence of glucose, an equilibrium of cholate between the inside and outside of the cells 
was obtained (Figure 4.4 A and B, solid lines). Upon addition of glucose cholate accumulated 
transiently. This is likely to be due to an increase in ~pH (interior alkaline). Cholic acid is a 
weak acid, pKa of 6.4, which in its undissociated form, diffuses across the cell membrane. It 
then becomes trapped in the cytoplasm as cholate In a pH-dependent fashion 
[Yokota et al., 2000]. The influx of cholate occurs whether or not ctrans is expressed. In the 
absence of pSKctrans a new equilibrium is reached, which is at a similar level to the de-energized 
cells (Figure 4.4 B). When pSKctrans is present, the initial accumulation of cholate is followed 
by a decrease in the level of cholic acid associated with the cel1 (Figure 4.4 A). Glucose 
metabolism results in a build up of ATP. The ATP is hydrolyzed so that the sodium gradient 
necessary to drive the cholate transporter is built up. The activity of ctrans is, therefore, strong 
enough to overcome the ~pH-dependent passive influx of cholate. 
4.5 CONCLUSIONS 
The efflux negative mutant, E. coli KAM3, was used to express the putative cholate transporter. 
While the expression of genes from Gram-positive, G+C-rich bacteria in a heterologous Gram-
negative host is not ideal, it was utilized in this study. This was done since there are currently no 
available Gram-positive efflux mutants that have been characterized in terms of expression of 
antibiotic resistance genes. In addition, as mentioned in Chapter 1, Section 1.2, there are no 
genetic methods by which specific genes can be inactivated in bifidobacteria. It is, therefore, not 
possible to ascertain whether BL1102 is essential for B. !ongum to survive in the presence of bile 
salts such as cholate. 
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The results reported in this chapter, show that when expressed in E. coli, pSKctrans mediates the 
energy-dependent efflux of cholate. This supports the notion that BL 1102 codes for an energy-
dependent cholate transporter. This is the first bile transporter described in bifidobacteria. 
The active efflux of bile salts has been described in both Gram-negative and Gram-positive 
bacteria. However, Kurdi et at (2003) observed that cholic acid, the main free bile acid produced 
by BSH activity in the intestine, accumulated in bifidobacteria. This occurred as long as the 
bacteria were energized. They postulated that this may benefit the mammalian host since the 
entrapment of free bile acids may decrease the production of secondary bile acids which are 
considered cytotoxic and precarcinogenic. The enzyme responsible for this reaction has not been 
found in bifidobacteria. It has yet to be shown, however, what benefit this would afford the 
bacteria itself since it has not been shown that bifidobacteria can derive any energy from bile 
salts. 
The study by Kurdi et at, (2003) was performed on 8 different bifidobacterial strains. However, 
neither B. longum NCC2705 nor B. long~l1n NCIMB 702259T were used. Therefore, BLl] 02 
which was identified in strain NCC2705 and isolated from NCIMB 702259T , may not have been 
present in the strains tested by Kurdi et al. Alternatively, BLl102 may not be constitutively 
expressed, or not expressed at high enough levels under the conditions tested to overcome the 
effect of the ilpH-driven passive influx of cholic acid. Yokota et al. (2000) only showed the 
ATP-dependent efflux of cholate in L. lactis strain C41-2. This cholate-resistant strain was 
derived from the wild-type L. lactis strain MG 1363 through growth on media containing 
stepwise-increasing cholate concentrations. No cholate efflux was observed in the wild-type 
strain. Using the protocol described in Section 4.3.6, they observed that in the wild-type strain, 
following the addition of glucose, cholate accumulated to a level at which the internal 
concentration was 7-fold higher that that of the extracellular medium [Yokota et ai, 2000]. 
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Future investigations into the role of BL1102 in conferring cholate resistance on bifidobacteria 
should include expression studies, such as northern hybridization. RNA isolation under 
conditions such as pre-exposure to low levels of cholk acid, would show whether the expression 
of BL1102 is bile-dependent. An alternative method to investigate the conditions under which 
BLlI02 is expressed would be real-time PCR (RT-PCR). Using this method, RNA would be 
isolated under conditions such as growth in low concentrations of bile. This would be followed 
by eDNA synthesis and quantitative RT-PCR. This method has been used successfully in Vibrio 
cholerae [Chatterjee et al., 2004] and Pseudomonas aeruginosa [Yoneda et ai., 2005J to study 
the expression of multi drug efflux pumps. Yoneda et al. (2005) found that this method was 
highly reproducible and allowed for the precise quantification of minute or substantial amounts 
of mRNA transcripts. The conditions under which BLl1 02 is expressed would also shed light 
onto the significance of the role that this gene plays in enabling B. !ongum to resist the effects of 
bile in the human GlT. 
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CHAPTERS 
GENERAL CONCLUSIONS 
Safety concerns regarding the consumption of probiotic-containing food products, are important 
factors in the selection of suitable candidate strains for use as probiotics. Bifidobacteria are 
generally considered to be good probiotics candidates and are already used extensively in 
fermented food products, such as yoghurt. It is, therefore, important to develop a science-driven, 
evidence based overview of the safety of their use as probiotics [Borriello et aI, 2003]. In 
particular, bifidobacteria have been shown to exhibit resistance to a wide range of antibiotics, but 
little is know about the molecular basis for this resistance. The aim of this project was, therefore, 
to investigate the molecular mechanisms responsible for the resistance against antibiotics and bile 
salts observed in bifidobacteria, and more specifically, to determine whether efflux systems 
contribute to this resistance. 
In this study, a wide range of antimicrobial agents were tested against selected bifidobacteria, and 
adaptation to at least one of the antimicrobial agents tested was observed in everyone of the 
bifidobacterial species under investigation. Bifidobacteria are resistant to a number of different 
antimicrobials with different targets and modes of action but this alone does not provide proof that 
multi drug efflux systems are responsible for the observed phenotypes. Antibiotic resistance in 
bacteria can be achieved via modification of the target of action, direct inactivation of the 
antibiotic, changes in the cell permeability and multidrug drug efflux pumps. The upregulation of 
multidrug efflux systems can provide cross-resistance to a number of antibiotics and/or 
antimicrobial agents [Levy, 2002], since the addition of the compounds exported by the multidrug 
transporters themselves actually enhances the expression levels of multi drug transporters 
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[Zheleznova et at., 1999]. In order to examine whether this is the case in bifidobacteria, future 
experiments should include the investigation as to whether pre-exposure of cells to one compound 
results in the increased resistance to another/other antimicrobial(s). 
In this study, genes conferring resistance to antimicrobials were identified using two approaches, 
namely the screening of a Bifidobacterium lactis genomic library in the drug hypersusceptible 
Escherichia coli KAM3. and the bioinformatic analysis of the Bifidobacterium longum genome 
sequence followed by functional complementation in E. coli KAM3. 
Only one efflux system was identified in B. lactis through the screening of a genomic library in 
E. coli KAM3 plated on media containing ethidium bromide or tetracycline. However, according 
to sequence analysis using TransportDB [www.membranetransport.org; described in Ren et al.. 
2004], there are at least 4 ABC multi drug transporters and 20 secondary multidrug transporters in 
B. [ongllm. The method used in this study may therefore be ineffective in identifying the vast 
number of multidrug transporters likely to be present in B. [actis. The genes in the B. longum 
NCC2705 genome sequence that showed sequence similarity to the ABC transporter cloned from 
B. [actis, namely BLOl54 and BL0155. are not, however, annotated as possible antibiotic extrusion 
systems. This illustrates that while genome analysis may identify many putative drug transporters, 
those with a novel signature sequence or membrane organization would be missed. Identification 
of drug efflux systems through functional complementation is, therefore, still a valid approach and 
more likely to identify novel drug transporters if they exist in Bifidobacterium spp. 
With the advent of whole genome sequencing, complete genome sequences can be systematically 
analyzed and predicted antimicrobial efflux proteins can be identified. This targeted approach 
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was, therefore, used to identify the cholate transporter, ctrans. E. coli KAM3 was used to express 
the putative cholate transporter. While the expression of genes from Gram-positive, G+C-rich 
bacteria in a heterologous Gram-negative host is not ideal, it was utilized in this study because of 
the scarcity of suitable Gram-positive drug-susceptible hosts. Using (~CJ-cholate, it was shown 
that pSKctrans mediated the energy-dependent eft1ux of cholate when expressed in E. coli. This is 
the first bile transporter described in bifidobacteria. 
Analysis of the expression of this gene in B. long urn would shed light onto the significance of the 
role that this gene plays in enabling B. longurn to resist the effects of bile in the human GIT. 
Future work could include the investigation into the conditions under which ctrans is expressed 
through the use of Northern hybridization or quantitative Real-Time PCR. 
While resistance to antimicrobial agents may increase the survival rate of bifidobacteria in the 
human GIT, one of the aspects which should be studied is the safety and risks of acquisition of 
antimicrobial agents [Sullivan and Nord, 2002], especially if these bacteria are to be added in high 
numbers to food products. It is currently difficult to interpret studies of gene transfer in vivo, and 
further methods need to be developed, particularly for bifidobacteria. Also, the focus should be on 
possible gene transfer to pathogenic bacteria such as Staphylococclis aureus, rather than on 
homologous gene transfer [Borriello et al, 2003]. In this context, studies such as this make a 
significant contribution to the fundamental knowledge of bifidobacteria, which is important if the 
probiotic industry is to contribute to human health. 
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APPENDIX A 
Preparation of Bifidobacterial Media 
A.l BHI Q!rain Hcart Infusion) Medium 
In rams er litre: 
Brain heart infusion (Difco) 37 
Yeast extract (Difco) 5 
Cystein HCl 0.5 
, Rezasurin 0.00] 
I Agar (if required) -'--]5 __ ---' 
A.2 BYG Q!asal+ Yeast + Glucose) Medium 
In rams er litre: 
Tryptone 
Yeast extract (Difco) 
Glucose 
Tween 80 
NaCI 
MgCh6H20 
I 
KHzP04 
KzHP04 
NH4CI 
10 
5 
5 
1 
4.5 
0.15 
.0.4 
I
· 0.2 
.0.4 
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APPENDIX B 
B.I Bacterial Strains Used in this Study 
i Strain Genotype and relevant 
characteristics 
l Reference 
r-----------------------~~~~~~--------~----------------~-------
Bifulobacterium 
B. bifidum NCFB 2203 
B. breve NCFB 2257 
B.longum NCFB 2259 
B. lactis DSM 10140 
B. bifidum W 
Escherichia coli 
DHSa 
JM109 
KAM3 
Lactoccus lactis subsp. lactis 
NZ9000 
liLmrCD 
wild type NCFB, UK 
wild type NCFB, UK 
wild type NCFB, UK 
Industrial strain used in Darleon Distribution 
yoghurt 
Uncharacterized Dr L. Brown, Food 
Technology, Cape Technikon 
supE44 L1lac U 169 Sam brook et al., 1985 
(<jJ80IacZL1m 15) hsdR 17 
recA 1 endA] gyrA 96 thi-l 
relAl 
recA 1 supE44 end A 1 
hsdR17 gyrA96 relA 1 thi 
L1( lac-p roAB) 
Yanisch-Peron et al., 1985 
&lcrAB li(Iac-pro) supE thi Morita et al .. 1998 
hsdli5/ F'traD36 proA + B+ 
lacP lacZliMl5 
wild type 
MG1363, deletion 
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B.2 Plasmid Vectors Used in this Study 
I Plasmid vector 
Escherichia coli 
pEcoR251 
pMTl04 
pBluescript SK (pSK) 
Lactoccus iactis subsp. lactis 
I pNG8048 
Antibiotic resistance genes 
and relevant characteristics 
AmpicillinR 
Reference 
I 
Zabeau & Stanley, 1982 
AmpicillinR, 0.15 kb B. fragilis Wehnert et al., 1990 
fragment in pEcoR251 
AmpicillinR, [acZ' 
Chloramphenico]R, 
I Erythromycin', N;s;nA-
inducible promoter 
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Dn:dI < Bbvtl.( ....... < S:IoAI <3348 
AhaI < AatII lCIpeJ21 < _ 
TaqII 
TaqII 
3000 
Alp700l 
AhaII < HfndI 
Seal 
CdDI/Cfrf 
AYaI < PItuI 
PatI 
FapI 
v.pJ 
AvafI < 2l5OO 
Btl 
£co311 < GILII < Cfr101 
pEcoR251 
3349 
8OO/Seci/Styl 
8gIU 
11h111l 
XcaI < led 
Ndel 
1CIIpe32J < HoIII 
FIGURE B.t Restriction map ofpEcoR251 (Zabeau & Stanley, 1982) 
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BScript-SK 
2959 
au < NotI / )email 
BatxI < ScIcIJ < D:IGt 
8aniI / SI:Jd 
FIGURE B.2 Restriction map ofpBluescript SK (Stratagene, La Jolla, CA) 
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3000 
".-
Sail 
Bsu361 
BspHI 
\ 
Ncol· 
Asp7181 
Kpnl 
Sma I 
Hpall 
Sacl 
......... Nsil .................................................................. EcoRI 
:: Hpal HindJII 
---'--..[- .: Pstl 
.' 
4000 
.Bcll 
Mlul 
Sail 
Aatll 
BamHI 
Sail 
pNG8048E 
1000 
Sail 
BamHI 
EcoRV 
B911 
................... _. Notl 
4379 bps 
2000 
\ 
Eco47111 
". 
Xhol 
Xmalll 
Xbal 
Sacl 
Hindlll 
FIGURE B.3 Restriction map ofpNG8048E (NIZO Food Reseach, The Netherlands) 
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